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1 Abstract 
1.1 Abstract 
The knockdown of proteins allows the study of protein functions in vitro and in vivo. Although RNA 
interference (RNAi) can be used for this purpose on the posttranscriptional level, knockdown 
strategies using intracellular antibodies (intrabodies) are an alternative acting on the 
posttranslational level.  
 
This study presents the first functional knockdown of vascular cell adhesion molecule (VCAM-1) 
that is achieved by co-expression of VCAM-1 specific intrabodies. Therefore, a mammalian 
expression vector was generated encoding a VCAM-1 specific single chain variable fragment 
(scFv) genetically fused to the sequence KDEL, which leads to retention of the protein inside the 
endoplasmic reticulum (ER) of the cell. Transient transfection of VCAM-1 positive cells with this 
expression plasmid revealed a downregulation of VCAM-1 from the cell surface determined by flow 
cytometry and fluorescence microscopy. The knockdown of surface VCAM-1 was time-dependent 
and almost complete. Furthermore, intrabody mediated knockdown also impaired cell-cell 
interaction of formerly VCAM-1 positive cells with Jurkat lymphoma cells. These are endogenously 
expressing very late antigen (VLA-4), a physiological binding partner of VCAM-1. Finally, 
colocalization of the retained VCAM-1 antigen and the co-expressed VCAM-1 specific intrabodies 
was analyzed by confocal microscopy, supporting the hypothesis that specific interaction of antigen 
and intracellular antibody downregulates the surface protein.  
 
Taken together, posttranslational knockdown of surface proteins by co-expression of ER-retained 
intrabodies is a promising technique, as shown here for the cell adhesion molecule VCAM-1.  
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1.2 Zusammenfassung 
Der Knockdown von Proteinen erlaubt die Analyse der Protein-Funktionen in vitro und in vivo. Die 
Methode der RNA-Interferenz (RNAi) kann zu diesem Zweck auf posttranskriptionaler Ebene 
benutzt werden, wohingegen Knockdown-Strategien mittels intrazellulärer Antikörper (intrabodies) 
eine Alternative sind, die auf posttranslationaler Ebene wirkt.  
 
Das Ziel dieser Arbeit war der funktionelle Knockdown des Oberflächenproteins VCAM-1 (vascular 
cell adhesion molecule) durch Koexpression von VCAM-1-spezifischen intrazellulären Antikörpern. 
Es wurde ein Expressionsvektor konstruiert, der ein Antikörperfragment gefolgt von einer 
C-terminalen KDEL-Sequenz kodierte, die für den Verbleib des Proteins im endoplasmatischen 
Retikulum (ER) der Zelle verantwortlich ist. Nach einer transienten Transfektion von VCAM-1 
positiven Zellen mit diesem Plasmid konnte mittels Durchflusszytometrie und 
Fluoreszenzmikroskopie eine Herunterregulierung des VCAM-1 Oberflächenproteins gezeigt 
werden. Der Knockdown von VCAM-1 war zeitabhängig und nahezu vollständig. Außerdem führte 
der Knockdown von VCAM-1 zu einer geringeren Bindung von zuvor VCAM-1 positiven Zellen an 
Jurkat-Zellen. Diese exprimieren das Integrin VLA-4 (very late antigen) endogen, den 
physiologischen Interaktionspartner von VCAM-1. Schließlich konnte mittels konfokaler 
Mikroskopie die Kolokalisation des intrazellulären VCAM-1 Antigens und des koexprimierten 
VCAM-1-spezifischen Antikörpers gezeigt werden. Diese Kolokalisation unterstützt die Hypothese, 
dass die spezifische Interaktion zwischen Antigen und intrazellulärem Antikörper zu einer 
Herunterregulierung des Oberflächenproteins führt.  
 
Zusammenfassend scheint der posttranslationale Knockdown von Proteinen durch Koexpression 
von intrazellulären Antikörpern eine vielversprechende Methode zu sein, die hier anhand des 
Zelladhäsions-Moleküls VCAM-1 gezeigt wurde.  
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2 Introduction  
2.1 Antibodies and antibody fragments 
Antibodies, also known as immunoglobulins (Ig), are an important element of the immune system 
of vertebrates (beginning with the class of gnathostomata). They are produced by B cells and are 
found in blood and in other extracellular fluids. Antibodies specifically bind to exogenous antigens 
like viruses, bacteria, fungi or toxins. Five different antibody isotypes are known: IgA, IgD, IgE, IgG 
and IgM. The isotypes have defined roles in the immune system with various localizations and 
different effector functions. Antibodies of the isotype IgG are the predominant isotype in the human 
serum and are responsible for the immunity against invading pathogens (Janeway, 2004).  
IgGs are proteins composed of four peptide chains: two identical heavy chains (HC) and two 
identical light chains (LC) (Fig. 2.1 A). An IgG has a molecular mass of about 150 kDa, each heavy 
chain accounts for 50 kDa and each light chain for 25 kDa. Both heavy chains are linked to each 
other and to a light chain via disulphide and non-covalent bonds. The heavy chain of IgGs 
constitutes of four different regions with various functions. The variable region (VH) represents the 
N-terminal part of the heavy chain, followed by a constant domain (CH1). The hinge region is 
responsible for the flexibility and the C-terminal constant domains (CH2 and CH3) mediate 
activation of complement or binding of effector cells via their Fc receptors. The light chain consists 
of two domains: the N-terminal variable (VL) and the C-terminal constant part (CL) (Abbas et al., 
2007).  
 
VH VL
linker
IgG scFv
A                                                               B
 
Fig.  2.1: Schematic representation of antibody and antibody fragment 
The assemblies of immunoglobulin G (IgG) and of a scFv fragment are shown. CH1, CH2, CH3, 
CL: constant domains of heavy or light chain; Fab fragment: consists of one constant and one 
variable domain from each heavy and light chain; Fc part: responsible for activation of complement 
and for binding of macrophages; Fv: variable part of an antibody that is responsible for the 
specificity; scFv: Fv fragment that is stabilized with a peptide linker; S-S: disulphide bonds; VH: 
variable domain of the heavy chain; VL: variable domain of the light chain. Modified based upon a 
drawing published before (Dübel, 2007).  
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The variable regions of heavy and light chain together form the antigen binding site of an antibody. 
This “Fragment variable” (Fv) is the smallest antigen binding entity, but the two polypeptide chains 
are only connected via intermolecular non-covalent bonds and therefore a Fv is quite unstable. The 
most commonly used small recombinant antibody format is the scFv fragment (single chain 
Fragment variable). In this protein, the variable regions of the N-terminal heavy (VH) and the 
C-terminal light (VL) chain are connected via a short polypeptide linker and are therefore part of 
one polypeptide chain (Fig. 2.1 B) (Janeway, 2004).  
 
2.2 Intracellular antibodies 
Intracellular antibodies (intrabodies) are defined as antibody molecules which are expressed 
intracellularly and which are located to defined subcellular compartments (Kontermann, 2004). The 
most frequently used format for intrabodies is the scFv fragment. To direct intrabodies to the 
subcellular compartment where the antigen of interest is located, signal sequences are genetically 
fused to the antibody molecule. There is a variety of signal sequences available, which are guiding 
the antibody to compartments such as mitochondria, nucleus, endoplasmic reticulum (ER), trans-
Golgi network (TGN), and plasma membrane (Fig. 2.2) (Persic et al., 1997). The intrabody is 
retained in the cytoplasm of the cell without any signal peptide (Cardinale et al., 2004). 
 
 
 
Fig.  2.2: Subcellular localization of intrabodies 
Intrabodies are expressed intracellularly and can be directed to the cytoplasm (1), the 
mitochondria (2), the nucleus (3), the endoplasmic reticulum (ER) (4), the trans-Golgi 
network (TGN) (5), the plasma membrane (6), or they can be secreted into the extracellular 
space (7) (Kontermann, 2004).  
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Antibody fragments contain N-terminal leader peptides to ensure the secretion of the scFv either 
into the periplasmic space of Escherichia coli (E. coli) or into the culture medium surrounding 
mammalian cells. The variable regions VH and VL are connected via a peptide linker and the 
c-myc and (His)6-tags are located C-terminally to allow detection or purification of the scFv. To 
redirect an antibody fragment to the ER of a mammalian cell, the C-terminal amino acid sequence 
Lys-Asp-Glu-Leu (KDEL) can be used (Munro et al., 1987). The schematic representation of an 
ER-retained antibody fragment is shown in figure 2.3.  
VH VL
linker
tags
KDEL
leader
 
 
Fig.  2.3: Schematic representation of an ER-retained scFv fragment 
The scFv fragment contains the N-terminal leader peptide (light grey), followed by the 
variable domains VH and VL that are fused by a flexible linker peptide (dark grey). The 
C-terminus consists of the c-myc and (His)6-tags (purple) and the ER-retention sequence 
KDEL (black) (modified based upon Dübel, 2007).  
 
 
 
2.2.1 Mechanism of target protein knockdown via ER-retained antibodies 
Mammalian cell surface proteins or secreted proteins are expressed and then transported through 
the ER and the Golgi network of the cell. These target proteins can be downregulated by using ER-
retained antibodies (Lo et al., 2008).  
The functional knockdown of a target protein by ER-retained antibodies can be described in four 
steps (Fig. 2.4). The initial situation is a mammalian cell, which is expressing the target protein on 
its cell surface (Fig. 2.4 A, target protein shown in green). The cell is carrying the genetic 
information for this target protein and after transcription and translation the protein is transported to 
the cell surface, passing through the ER, the Golgi network and secretory vesicles. In a second 
step, the cell is transiently transfected with an expression plasmid encoding an intrabody specific 
for the target protein (Fig. 2.4 B, antibody gene shown in red). The intrabody containing the KDEL-
sequence is expressed and binds to its target protein (Fig. 2.4 C). Inside the cis-Golgi network, the 
sequence KDEL binds to a receptor (hERD2) and the complex consisting of intrabody and target 
protein is transported through the Golgi apparatus back to the ER, where the scFv-target protein 
complex is released (Böldicke, 2007). This intracellular retransfer is called “retrograde pathway” 
and leads to a retention of the complex of intrabody and target protein inside the cell. As a result, 
the cell surface becomes negative for the target protein, because all freshly expressed target 
proteins are withheld inside the cell (Fig. 2.4 D).  
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Fig.  2.4: Knockdown of a target protein by ER-retained antibodies 
The four steps of knockdown by intrabodies are shown: initial situation of mammalian cell (A), transfection with 
plasmid encoding ER-retained antibody (B), expression of the ER-retained antibody (C), and knockdown of 
surface protein (D). The target protein and its appropriate gene are shown in green, whereas the intrabody and 
its gene appear in red (modified based upon an unpublished drawing by Dübel).  
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2.2.2 Therapeutic applications of intrabodies 
Intrabodies in infectious diseases 
Molecules targeted with the intracellular antibody method include viral antigens in the context of 
human immunodeficiency virus (HIV) infection. Almost all of the 15 proteins of HIV-1 have been 
targeted by intrabodies: HIV structural proteins (matrix, nucleocapsid and envelope), enzymes 
(integrase and reverse transcriptase) and regulatory proteins (Tat, Rev and Nef) (Rondon et al., 
1997). These intrabodies efficiently inhibited HIV-1 production in host cells. In one of these studies 
CD4+ T cells from HIV-infected patients were transduced with an anti-Tat intrabody gene using 
retroviral vectors. Although only 20% of cells were transduced, HIV-1 replication was suppressed in 
the entire culture (Poznansky et al., 1998). Another study showed that CD4+ lymphocytes 
transduced with an anti-gp120 intrabody expression cassette using an adeno-associated virus 
were resistant to infection by several primary HIV-1 patient isolates (Chen et al., 1994).  
Gene transfer of intrabodies directed towards HIV aims at blocking the viral cycle at various stages, 
as well as halting the mechanisms of pathogenesis. The rationale for delivering anti-HIV genes to 
CD4+ T cells is to protect the cells that are directly targeted by the infection, as well as to slow 
down HIV replication in cells that are already infected (Paillard, 1999).  
 
Intrabodies in tumor therapy 
Intrabodies also have been extensively studied as inhibitors of tumor associated antigens. ErbB-2 
(also known as HER2/neu) is a tumor associated antigen that is overexpressed by a variety of 
tumors including breast and ovary carcinoma. It is a member of the epidermal growth factor 
receptor (EGFR) family and a receptor tyrosine kinase. ErbB-2 is involved in signal transduction 
pathways regulating cell growth and differentiation (Ménard et al., 2004).  
An ER-retained ErbB-2 specific antibody led to retention of the receptor molecules in the ER and to 
a phenotypic knockout of ErbB-2 on the cell surface. Tumor cell proliferation was impaired in vitro 
(Beerli et al., 1994) and in vivo (Deshane et al., 1995) and apoptosis of the tumor cells was 
induced. In animal models, anti-neoplastic effects were observed after adenovirus-mediated 
transfer of the intrabody-encoding gene into ovarian cancers (Deshane et al., 1997). Due to 
antitumor activity, survival in ovarian cancer animal models was prolonged. Finally, a phase I trial 
was done with ovarian cancer patients using intraperitoneal administration of an adenovirus 
carrying the ER-retained anti-erbB2-scFv-KDEL intrabody (Alvarez et al., 2000). However, only a 
limited number of tumor cells were transduced and none of the patients treated showed clinical 
benefits.  
Therefore, gene therapy with intrabodies seems to be feasible, but efficient and safe gene transfer 
systems still have to be developed.  
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2.3 Vascular Cell Adhesion Molecule 1 (VCAM-1) 
VCAM-1 (CD106) is a type I transmembrane protein and is a member of the immunoglobulin gene 
superfamily (Osborn et al., 1989). The structure of proteins belonging to the immunoglobulin gene 
superfamily is characterized by repeated domains, similar to those found in immunoglobulins build 
from a tightly packed barrel of β-strands. VCAM-1 consists of an N-terminal extracellular part 
containing seven immunoglobulin domains, a transmembrane part and a short C-terminal 
intracellular domain (Fig. 2.5). There are two different forms of VCAM-1, one form with seven 
immunoglobulin domains and an alternatively spliced form with six immunoglobulin domains 
(lacking the fourth Ig-like domain) (Cybulsky et al., 1991). Depending on the amount of 
glycosylation, VCAM-1 has a size of approximately 90–110 kDa. VCAM-1 is absent on resting 
endothelial cells, but it can be upregulated by inflammatory mediators like interleukin (IL)-1β, IL-4, 
tumor necrosis factor alpha (TNF-α) and interferon gamma (IFN-γ) (Shimizu et al., 1992). It is found 
in biologically active form in serum, probably due to proteolytic cleavage from the cell surface 
(Gearing et al., 1992). VCAM-1 has been conserved through evolution. Concerning the amino acid 
sequence, rat and mouse VCAM-1 are 77% and 76% homologous to human VCAM-1, respectively 
(Hession et al., 1992).  
 
 
 
Fig.  2.5: Structure of vascular cell adhesion molecule (VCAM-1) 
VCAM-1 is a type I transmembrane protein. The N-terminal part of the protein is located 
outside of the membrane, whereas the C-terminus is situated inside the cell. The VCAM-1 
protein shown here is the seven immunoglobulin (Ig) domain form (Kobayashi et al., 2007).  
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2.3.1 VCAM-1 in health: The extravasation cascade of leukocytes 
Leukocyte extravasation is the movement of leukocytes from the blood system to a site of tissue 
damage, infection or inflammation. The leukocytes interact in a sequential fashion with adhesion 
molecules on the vascular endothelium, rolling along the endothelial surface until firmly attached, at 
which point they extravasate to the target tissues (Ebnet et al., 1999). The three steps rolling, firm 
adhesion and extravasation of leukocytes are shown in figure 2.6.  
 
Rolling (1). The first step of leukocyte extravasation involves the reversible binding of leukocytes 
to vascular endothelium. This interaction is mediated between selectins induced on the 
endothelium (Kansas, 1996) and their carbohydrate ligands on leukocytes (Hidalgo et al., 2007). 
Figure 2.6 shows the interaction between P-selectin and its counter part PSGL-1 (P-selectin 
glycoprotein ligand 1) and the binding of E-selectin to its ligand sialyl-Lewis moiety (sLe) (Berg et 
al., 1991). However, this relatively weak interaction cannot firmly adhere the leukocytes and due to 
blood flow, the leukocytes start to roll along the endothelium of the blood vessel.  
 
 
Fig.  2.6: The extravasation cascade of leukocytes 
Leukocytes interact in a sequential fashion with adhesion molecules on vascular endothelium; 
(1.) Rolling along the endothelial surface; (2.) Firm adhesion to endothelium; (3.) Extravasation of 
leukocytes to targeted tissues. (Modified based upon Kobayashi et al., 2007).  
 
Firm adhesion (2). Inflammatory mediators activate surface integrins on leukocytes (Mac-1, LFA-1 
and VLA-4) and the integrins switch from their low-affinity to a high-affinity state. Additionally, 
adhesion molecules (MadCam-1, ICAM-1 and VCAM-1) are upregulated on the activated 
endothelium. The firm adhesion of leukocytes to the endothelial cells is mediated through an 
interaction of the high-affinity integrins on leukocytes and the endothelial cell adhesion molecules. 
One of these interactions is the binding of VCAM-1 to the α4β1 integrin VLA-4. VCAM-1/VLA-4 
interaction mediates firm adhesion of circulating leukocytes to activated endothelium (Sharar et al., 
1995). Therefore, leukocytes are immobilized although the blood is flowing. 
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Extravasation (3). Leukocytes migrate through the endothelial cell layer. PECAM-1 (platelet 
endothelial cell adhesion molecule 1; CD31) is involved in this process, being expressed on 
leukocytes and in junctions of the endothelial cells. PECAM-1 molecules interact and pull the 
leukocyte through the endothelium (Woodfin et al., 2007). Finally, the leukocyte migrates along a 
concentration gradient of chemokines secreted by cells at the site of infection.  
 
 
2.3.2 VCAM-1 in disease 
Inflammatory disorders such as autoimmune diseases and graft rejection are mediated by 
leukocytes, which penetrate the inflamed tissue and are responsible for the immune reaction. 
Adhesion blockade in animal models prevents graft rejection and disease severity in autoimmune 
models. Clinical studies with humanized monoclonal antibodies that interfere with VLA-4/VCAM-1 
interaction have shown significant efficacy in autoimmune disease, including multiple sclerosis and 
inflammatory bowel disease. Thus, adhesion blockade is emerging as a useful therapeutic strategy 
in several inflammatory settings (Dedrick et al., 2003).  
Cell adhesion molecules additionally control extravasation of circulating cancer cells, which is a key 
step in metastasis. Some circulating cancer cells have been shown to extravasate using a process 
similar to inflammatory cells. This process may partially explain links between inflammation and 
tumorigenesis.  
There are two possible schemes for adhesion of cancer cells to endothelium: direct and indirect 
adhesion (Fig. 2.7).  
 
 
Fig.  2.7: Possible adhesion schemes of cancer cells to vascular endothelium 
Direct adhesion of cancer cell to endothelium (a) or indirect adhesion of cancer cell mediated by 
granulocyte (b). (Kobayashi et al., 2007).  
 
For direct adhesion (Fig. 2.7 A), the cancer cell is expressing integrins and other ligands on its 
surface, which bind to E-selectin, P-selectin, ICAM-1 or VCAM-1 on the endothelium. This direct 
interaction is very similar to the adhesion of leucocytes during inflammation.  
Moreover, VCAM-1 is involved in adhesion of tumor cells on endothelium. It is upregulated on 
endothelial cells through stimulation with TNF-α and tumor cell adhesion is enhanced. A VCAM-1 
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specific neutralizing antibody completely circumvented adhesion of tumor cells, indicating a 
potential role of VCAM-1 in tumor metastasis (Okada et al., 1999). Endothelial VCAM-1 was shown 
to be involved in TNF-α induced adhesion of primary prostate carcinoma cells (Brayton et al., 1998) 
and of renal cell carcinoma cells (Steinbach et al., 1996). Induction of cell adhesion molecules by 
cytokines seems to be involved in metastasis. This could explain the promoting role of inflammation 
in cancer progression (Kobayashi et al., 2007).  
 
For indirect adhesion (Fig. 2.7 B), the interaction of tumor cell and endothelium is mediated by 
granulocytes. These leukocytes bind both cancer and endothelial cells via cell adhesion molecules. 
It was shown that the adhesion of tumor cells to endothelium and the migration through the 
endothelium is increased in the presence of granulocytes (Slattery et al., 2003).  
Interestingly, the cell adhesion molecule VCAM-1 is highly overexpressed in several tumors. In 
renal cell carcinoma (RCC), it is thought to have a role in tumor immune escape (Wu, 2007) and in 
human breast cancer patients VCAM-1 expression in tumor tissues and serum was higher than in 
patients with benign tumors (Regidor et al., 1998).  
 
2.4 Objectives of this study 
The main goal of this study was the functional knockdown of surface VCAM-1 by using ER-retained 
antibodies. Starting with a hybridoma cell line expressing a VCAM-1 specific antibody, the genetic 
information of the variable heavy and light chain should be isolated and cloned into a prokaryotic 
expression vector. Afterwards, it should be shown that the generated VCAM-1 specific scFv 
antibody fragment is still binding to VCAM-1 antigen.  
A cell line stably expressing a VCAM-YFP fusion antigen should be generated, containing an 
intracellular yellow fluorescence protein (YFP) and the extracellular VCAM-1 moiety. Furthermore, 
a mammalian expression vector should be designed that contains the VCAM-1 specific 
ER-retained intrabody fragment for later use as knockdown construct.  
The generated VCAM-1 positive cell line should be transfected with this knockdown intrabody 
construct. The resulting knockdown of surface VCAM-1 should be analyzed by using flow 
cytometry and fluorescence microscopy. Additionally, cell-cell adhesion assays should be used to 
show the functionality of the VCAM-1 knockdown. Finally, the colocalization of the VCAM-1 specific 
intrabody and the retained VCAM-YFP fusion antigen should be visualized by using confocal 
microscopy.  
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3 Materials and Methods 
3.1 Materials 
3.1.1 Consumables 
All consumables used in this study are listed in table 3.1.  
Tab.  3.1: Consumables 
 Product Supplier Catalog 
number 
Pipettes (2 mL) Greiner, Germany  
Pipettes (5 mL) Greiner, Germany 606180 
Pipettes (10 mL) Sarstedt, Germany 86.1254.001 
Pipettes (25 mL) Greiner, Germany  
Tips for pipettes (10 µL) Sarstedt, Germany 70.1130 
Tips for pipettes (200 µL) Sarstedt, Germany 70.760 
Tips for pipettes (1000 µL) Sarstedt, Germany 70.762 
Tips for pipettes (5 mL) Eppendorf, Germany  
PCR tubes Greiner, Germany  
PCR tubes Sarstedt, Germany  
Polypropylene tubes (15 mL) Corning, USA 430791 
Polypropylene tubes (50 mL) Corning, USA 430829 
Micro centrifuge tubes  Sarstedt, Germany  
Filter (0.45 µm) Sartorius, Germany 16555 
General 
Filter (0.20 µm) Sartorius, Germany 17823 
Petri dishes Greiner, Germany 633180 E. coli culture 
Micro tubes (PP) (2 mL) Sarstedt, Germany 72.694.006 
Tissue culture dishes  Sarstedt, Germany 83.1802 
6-well plates Greiner, Germany 657160 
24-well plates Greiner, Germany  662160 
96-well plates Greiner, Germany  655180 
Cell culture 
Cryo tube vials (2 mL) Nunc, Germany 375418 
Western blot PVDF membrane  Carl Roth, Germany T830.1 
96-well plates  Falcon, BD, USA 353912 ELISA 
96-well plates (MaxiSorp) Nunc, Germany 430341 
Flow 
cytometry 
5 mL tubes (PP) Greiner, Germany  115201 
Surface 
plasmon 
resonance 
Sensor chip CM5 GE Healthcare, USA 22-0512-32 
 
 
3.1.2 Technical equipment 
The technical equipment used in this study is listed in table 3.2.  
Tab.  3.2: Technical equipment 
Product class Specific type Supplier 
Analytical balance Model 1205MP Sartorius, Germany 
Blotting device Semi-dry transfer cell (trans blot SD) Bio-Rad, Germany 
Biofuge pico Heraeus, Germany 
Eppendorf 5415 D Eppendorf, Germany 
Eppendorf 5810R Eppendorf, Germany 
Centrifuge 
Multifuge 3 S-R Heraeus, Germany 
LaminAir HLB 2472  Heraeus, Germany Clean bench 
Herasafe Heraeus, Germany 
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DNA electrophoresis Model 40-0708  Peqlab, Germany 
DNA sequencer  ABI prism 310 genetic analyzer Applied Biosystems, 
Perkin Elmer, USA 
Electrophoresis Electrophoresis power supply  
EPS 601/301 
Amersham, Sweden  
ELISA washer Columbus Plus Tecan, Germany 
ELISA reader Tecan sunrise Tecan, Germany 
Flow cytometer FC 500 Beckman Coulter, USA 
Fluorescence 
microscope 
Axiophot Zeiss, Germany 
Microtiter plate shaker Microtiter plate shaker Lab4You, Germany 
PCR machine  PTC-150 minicycler MJ Research, USA 
Protein electrophoresis Mini protean 3 system Bio-Rad, Germany 
Äkta prime GE Healthcare, USA Protein purification 
HiTrap Protein G HP column (1 mL) GE Healthcare, USA 
Spectrophotometer Nano-Drop ND – 1000 Thermo, USA 
Surface plasmon 
resonance 
Biacore 2000 GE Healthcare, USA 
Thermo mixer  Thermo mixer comfort Eppendorf, Germany 
Ultra-pure water device  Arium 611 Sartorius, Germany 
 
 
3.1.3 Chemicals 
All chemicals used were purchased from Sigma, Merck or Carl Roth (all located in Germany). 
 
 
3.1.4 Buffers and solutions 
All buffers and solutions used in this study are listed in table 3.3. They were either prepared with 
ultra pure water or as indicated.  
Tab.  3.3: Buffers and solutions 
 Solution Recipe 
PBS (20x) 170 g/L NaCl 
26.8 g/L Na2HPO4 x 2H2O 
6.9 g/L NaH2PO4 x 2H2O 
TE buffer (pH 8.0)  
 
10 mM Tris-HCl 
1 mM EDTA (pH 8.0) 
General 
EDTA (pH 8.0) 0.5 M EDTA 
TAE buffer 
 
40 mM Tris-HCl 
20 mM Acetic acid 
1 mM EDTA (pH 8.0) 
DNA 
electrophoresis 
Ethidium bromide solution 
 
10 mg/mL 
0.01% (w/v) Ethidium bromide 
Binding buffer (pH 7.0) 20 mM Sodium phosphate 
Elution buffer (pH 2.7) 0.1 M Glycine-HCl 
Protein 
purification via 
protein G Neutralization buffer  
(pH 9.0) 
2 M Tris-HCl 
 
Acrylamide mix  
 
30% (w/v) Acrylamide 
0.8% (w/v) Bisacrylamide 
Buffer for running gel 
(pH 8.8) 
1.5 M Tris-HCl 
Buffer for stacking gel 
(pH 6.8) 
1 M Tris-HCl 
SDS-PAGE 
 
APS solution 10% (w/v) (NH4)2S2O8 
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Laemmli’s sample buffer  
(5x) 
50% (v/v) Glycerol 
10% (w/v) SDS 
25% (v/v) β-Mercaptoethanol 
20% (v/v) Tris-HCl (pH 6.8) 
0.05% (w/v) Bromophenol blue 
 
Running buffer 
 
25 mM Tris-HCl 
192 mM Glycine 
0.1% (w/v) SDS 
Staining solution 30% (v/v) Ethanol 
10% (v/v) Acetic acid 
0.25% (w/v) Coomassie brilliant blue G-250 
Coomassie 
staining 
Destaining solution 40% (v/v) Ethanol  
10% (v/v) Acetic acid 
Western blot 
 
Blotting buffer 
 
25 mM Tris 
192 mM Glycine 
PBS/BSA 2% (w/v) BSA in PBS 
Substrate buffer (pH 9.5) 
 
100 mM Tris-HCl 
0.5 mM MgCl2  
BCIP solution 15 mg/mL BCIP in DMF 
Immunostain 
NBT solution 30 mg/mL NBT in 70% DMF 
Coating buffer (pH 9.6) 100 mM NaHCO3 
PBS-T 0.05% (v/v) Tween 20 in PBS 
PBS/FCS 50% (v/v) FCS in PBS 
TMB solution A (pH 4.1) 30 mM Potassium citrate 
0.5 mM Citric acid 
TMB solution B 10 mM Tetramethylbenzidine (TMB) 
10% (v/v) Acetone 
90% (v/v) Ethanol 
80 mM H2O2 (30%) 
ELISA 
Stopping solution 1 N H2SO4 
PBS-T 
 
0.005% (v/v) Tween 20 (free of peroxide)  
in PBS 
EDC 75 g/L 
NHS 11.5 g/L 
BSA (pH 4.5) 2 µg/mL 
Ethanolamine (pH 8.5) 1 M 
Biacore 
 
Acetate buffer (pH 4.0) 10 mM Sodium acetate 
Lysis of cells Lysis buffer (pH 7.6) 10 mM Tris 
150 mM NaCl 
1% Nonidet P-40 
5 mM EDTA 
1 mM PMSF 
Fixation 2% (v/v) Formaldehyde in PBS 
Buffer A 0.5% (w/v) BSA 
0.1% (w/v) Sodium azide in PBS 
Flow cytometry 
Buffer B 0.5% (w/v) BSA 
0.5% (w/v) Saponin 
0.1% (w/v) Sodium azide in PBS 
Fixing solution 3.7% (v/v) Formaldehyde Fluorescence 
microscopy Blocking buffer 0.1% (w/v) BSA in PBS 
Cellular assays D-PBS (10x) 2 g/L KCl 
2 g/L KH2PO4 
80 g/L NaCl 
14.4 g Na2HPO4 x 2H2O 
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3.1.5 Materials for culture and storage 
3.1.5.1 Prokaryotes 
All media and solutions used for culture of E. coli are listed in table 3.4. 
Tab.  3.4: Media and solutions used for culture of E. coli 
 Solution Recipe 
2xYT 
 
1.0% (w/v) Bacto yeast extract 
1.6% (w/v) Bacto tryptone 
0.5% (w/v) NaCl 
2xYT-A  
 
2xYT medium 
100 µg/mL Ampicillin 
2xYT-GA 
 
2xYT medium 
100 µg/mL Glucose 
100 µg/mL Ampicillin 
Medium 
SOC 
 
0.5% (w/v) Bacto yeast extract 
2.0% (w/v) Bacto tryptone 
0.05% (w/v) NaCl 
pH 7.0 
after autoclaving add: 
20 mM MgCl2 solution 
20 mM Glucose 
Agar 2xYT agar 1.5% (w/v) Agar in 2xYT medium 
Mg2+ solution 
 
1 M MgCl2 
1 M MgSO4  
Glucose solution 2 M Glucose 
Ampicillin solution 100 mg/mL Ampicillin 
working concentration: 100 µg/mL 
Tetracycline solution 5 mg/mL Tetracycline in Ethanol 
working concentration: 50 µg/mL 
Solutions 
IPTG 1 M IPTG in dH2O 
working concentration: 50 µM 
 
 
3.1.5.2 Eukaryotes 
All media, solutions and supplements used for culture of mammalian cells are listed in table 3.5. 
Tab.  3.5: Media, solutions and supplements used for culture of mammalian cells 
Product Supplier Catalog number 
RPMI 1640 medium PAA, Austria E15-840 
DMEM medium PAA, Austria E15-810 
ISF-1 medium Invivo, Biochrom, Germany M001 
Trypsin/EDTA  PAA, Austria L11-004 
Accutase PAA, Austria L11-007 
Penicillin/streptomycin PAA, Austria P11-010 
L-Glutamine PAA, Austria M11-004 
G-418 PAA, Austria P02-012 
Fetal calf serum (FCS) Gibco, Invitrogen, USA 10084-168 
poly-L-Lysine Sigma, Germany P 4707 
DMSO Carl Roth, Germany 4720.1 
Nonidet P-40 
(Igepal CA630) 
ICN Biomedicals, Germany 198596 
Cell Tracker CM-DiI Molecular Probes/ Invitrogen, USA C7000 
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3.1.6 Strains of bacteria 
The bacterial strains used in this study are listed in table 3.6. 
Tab.  3.6: Bacterial strains 
E. coli strain Genotype Supplier 
XL1-Blue-MRF’ K12 strain: ∆(mcrA)183 ∆(mcrCB-hsdSMR-mrr)173 
endA1 supE44 thi-1 recA1 gyrA96 relA1 lac [F´ 
proAB lacIqZ∆M15 Tn10 (Tetr)] 
Stratagene, USA 
 
 
 
3.1.7 Eukaryotic cell lines 
All eukaryotic cell lines used are listed in table 3.7. 
Tab.  3.7: Eukaryotic cell lines 
Cell line Description Supplier 
HEK-293 Immortalized human embryonic kidney cells ATCC (CRL-1573) 
HEK-293T Immortalized human embryonic kidney cells ATCC (CRL-11268) 
6C7.1 Rat hybridoma specific for murine VCAM-1 Engelhardt et al., 1998 
Jurkat Human acute T cell leukemia cell line ATCC (TIB-152) 
 
 
3.1.8 Expression vectors 
The plasmids used in this study are listed in table 3.8. 
Tab.  3.8: Expression vectors 
Plasmid Description Supplier 
pOPE101 Prokaryotic expression vector Schmiedl et al., 2000 
pCMV/myc/ER Mammalian expression vector Invitrogen, USA 
pCS-Venus Mammalian vector for intracellular expression 
of the YFP derivate Venus 
Nagai et al., 2002 
 
 
3.1.9 Oligonucleotides 
All oligonucleotides used in this study are listed in table 3.9. 
Tab.  3.9: Oligonucleotides 
Primer 
name 
Restriction 
site 
Sequence (5’- 3’) Function 
NS 21 for EcoRV GGTGAYATYCARATGACNCARWS
NCCNGCNWSNYTNWS 
Amplification of VL 
Bi5 rev 
 
BamHI GGGAAGATGGATCCAGTTGGTGC
AGCATCAGC 
Amplification of VL 
(Dübel et al., 1994) 
Bi3b for PstI CCAGGGGCCAGTGGATAGACAAG
CTTGGGTGTCGTTTT 
Amplification of VH 
(Dübel et al., 1994) 
Bi4 rev HindIII CCAGGGGCCAGTGGATAGACAAG
CTTGGGTGTCGTTTT 
Amplification of VH 
(Dübel et al., 1994) 
NS 5 for BssHII 
(delta BglII) 
ATATATGCGCGCACTCCTTTAAAA
TCGAAATCTCCCCTGAATAC 
Amplification of VCAM-1 
cDNA 
NS 8 rev BglII ATATATAGATCTCACTTTGGATTTC
TGTGCCTCC 
Amplification of VCAM-1 
cDNA 
NS 15Q for PstI ATATATGGCGCGCACTCCCAAGTT
CAGCTGCAGGAGTC 
Cloning of  
pOPE101-scFv6C7.1-
KDEL 
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NS 24 rev XbaI CAGGCCTCTAGATTATAGTTCGTC
CTTATGATGATGGTGATGATGGGA
TAGATCTTCTTC 
Cloning of  
pOPE101-scFv6C7.1-
KDEL 
# 144 for - GTGTTGACTTGTGAGCGG Amplification of scFv215 
# 255 rev - CTGATCATTAGCACAGGCC Amplification of scFv215 
 
 
3.1.10 Antibodies and antigens 
The antibodies and antigens used in this study are listed in table 3.10. 
Tab.  3.10: Antibodies and antigens 
Antibody or antigen Format Supplier Mono- or 
poly-
clonal 
Catalog 
number 
Unconjugated antibody 
Rat anti-murineVCAM-1 (6434) IgG1 R&D Systems, 
USA 
mono MAB6434 
Rat anti-murineVCAM-1 (6C7.1) 
 
IgG Self-produced mono - 
Mouse anti-(c)myc (9E10) IgG AG Dübel, TU 
Braunschweig, 
Germany 
mono hybridoma 
supernatant 
Mouse anti-His5  IgG1 Qiagen, 
Germany 
mono 34660 
Mouse anti-His6  IgG1 Roche, 
Germany 
mono 11922416 
HRP conjugated antibody 
Goat anti-mouse IgG (Fab-specific)-
HRP 
IgG Sigma, 
Germany 
poly A 2304 
AP conjugated antibody 
Goat anti-rat IgG (whole molecule)-
AP 
IgG Sigma, 
Germany 
poly A 8438 
Goat anti-mouse IgG (Fab-specific)-
AP 
IgG Sigma, 
Germany 
poly A 2179 
Goat anti-mouse IgG (Fab-specific)-
AP 
IgG Dianova, 
Germany 
poly 115-055-072 
Fluorescent antibody 
Goat anti-rat IgG (gamma-specific)-
APC 
F(ab’)2 Dianova, 
Germany 
poly 112-136-071 
Goat anti-rat IgG (H+L)-TRITC - Biomol, 
Germany 
poly 612-1002 
Goat anti-mouse IgG (H+L)-PE  
 
IgG Rockland, USA poly 610-108-121 
Goat anti-mouse-AlexaFluor546 
 
- Invitrogen, USA poly A11030 
Antigens 
Recombinant murine VCAM-1 antigen 
(mVCAM1-hum.Fc-His) 
human 
Fc-
fusion 
R&D Systems, 
USA 
- 643-VM 
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3.1.11 Software and databases 
All software and databases used are listed in table 3.11. 
Tab.  3.11: Software and databases 
Product Purpose Supplier 
VectorNTI Illustration and construction of plasmids Invitrogen, USA 
FinchTV 1.3.1 Presentation and analysis of DNA 
sequencing chromatograms 
Geospiza, USA 
Cytomics CXP Analysis of flow cytometry data Beckman Coulter, USA 
ImageJ Analysis of fluorescence microscopy 
images 
National Institutes of 
Health, USA 
LSM Image browser Analysis of confocal microscopy images Carl Zeiss, Germany 
 
 
3.2 Methods of molecular biology 
Protocols employed in this study are generally based on the methods described by (Sambrook et 
al., 2001). Modifications of these methods will be described below.  
 
3.2.1 Preparation of plasmid DNA 
Plasmid DNA was prepared from E. coli using NucleoSpin Plasmid kit (Macherey & Nagel, 
Germany) or GFX micro plasmid prep kit (GE Healthcare, USA). For transfection of mammalian 
cells, the DNA was isolated using the GenElute high performance plasmid midiprep kit (Sigma, 
Germany). The DNA was always eluted with sterile dH2O.  
 
3.2.2 Amplification of DNA by PCR 
For amplification of DNA by polymerase chain reaction (PCR), oligonucleotide primers were 
designed. Recognition sequences for restriction endonucleases were inserted via these primers at 
both ends of the generated DNA fragment. All oligonucleotides are listed in chapter 3.1.9 and were 
purchased from Operon (Germany).  
For amplification of the DNA of interest, PCR reactions of a total volume of 50 µL were prepared. 
CombiZyme polymerase (Invitek, USA) was used for amplification of DNA fragments. Annealing 
temperature (y) depended on the used oligonucleotide. Duration of the elongation step (z) was 
chosen according to the length of the DNA fragment to be amplified by CombiZyme DNA 
polymerase.  
 
Mixture for PCR     PCR program 
 
40-x  µL  H2O     1 94°C  1:00 min 
  5  µL OptiPerform buffer (10x)  2 94°C  1:00 min 
  2.5 µL MgCl (50mM)    3 y°C  1:00 min 
  1  µL dNTPs (10mM)    4 72°C  z:zz min 
  0.5  µL Forward primer (10pmol/µL)  5 goto 2  29x 
  0.5  µL  Reverse primer (10pmol/µL)  6 72°C  10:00 min 
  x  µL  DNA template    7 hold 16°C 
  0.5  µL CombiZyme    8 end 
50 µL  
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3.2.3 Agarose gel electrophoresis 
For analytical separation of DNA fragments, agarose gels consisting of 1% (w/v) agarose in TAE 
buffer (chapter 3.1.4) were prepared. Ethidium bromide was added to the gel in a final 
concentration of 100 ng/mL. The DNA samples were mixed with 6 x DNA loading dye (MBI 
Fermentas, Germany) and GeneRuler DNA Ladder Mix (MBI Fermentas, Germany) was used as a 
size standard. A current of 100 V and 400 A was applied for 40 min. Due to the intercalating 
ethidium bromide, the DNA was detected under UV light (λ = 312 nm) after electrophoresis.  
 
3.2.4 Purification of DNA 
DNA purification after PCR, enzymatic digestions or agarose gel electrophoresis was performed 
with NucleoSpin Extract II kit (Macherey & Nagel, Germany) or GFX PCR DNA and gel band 
purification kit (GE Healthcare, USA) according to the manufacturer’s instructions. DNA was eluted 
with sterile dH2O.  
 
3.2.5 Determination of DNA concentration and purity 
Concentration and purity of DNA were determined by measuring the absorbance at 260 nm and 
280 nm. For a pure DNA solution, an A260nm of 1 corresponds to a concentration of dsDNA of 
50 µg/mL. For a ratio of A260nm/A280nm = 1.8 – 2.0, the DNA can be considered to be pure.  
 
3.2.6 Digestion of DNA with restriction endonucleases 
Enzymatic DNA digestion was carried out using restriction endonucleases purchased from New 
England Biolabs (NEB, USA) or MBI Fermentas (Germany). Reaction buffers and incubation 
temperatures were chosen according to the manufacturer’s instructions. Digestion was done for up 
to 16 h and was followed by heat inactivation of the restriction enzymes (20 min, 65°C or 80°C). 
 
3.2.7 Dephosphorylation with CIP 
To avoid re-ligation of the digested vector DNA, the 5’ phosphate groups of the linearized plasmid 
were removed prior to ligation. 1 µL of calf intestinal alkaline phosphatase (CIP, NEB, USA) was 
added to the enzymatic digestion reaction immediately after restriction. It was incubated for 30 min 
at 37°C. Afterwards, the DNA was purified using a PCR purification kit (Macherey & Nagel, 
Germany) following the manufacturer’s instructions.  
 
3.2.8 Ligation of DNA 
DNA ligation was carried out using T4 DNA ligase (Promega, Germany) at 16ºC overnight. The 
molar ratio of vector to insert was 1:3. After ligation, the mixture was heat inactivated at 60°C for 
10 min and was used for transformation of competent E. coli cells. 
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3.2.9 Sequencing of DNA 
All plasmids derived by cloning via PCR were sequenced with an ABI prism 310 genetic analyzer 
(Applied Biosystems, USA). The sequencing reaction with fluorescence-labeled ddNTPs (BigDye, 
Applied Biosystems, USA) and the subsequent purification were carried out as described by the 
manufacturer. The analysis of all sequencing results was done using the software Finch TV and 
Vector NTI. 
 
3.2.10 Isolation of variable regions of antibody 6C7.1 and scFv construction 
The isolation of the variable regions of the VCAM-1 specific antibody 6C7.1 (variable light (VL) and 
variable heavy (VH) chain) was performed as described (Toleikis et al., 2004). The detailed 
procedure is outlined in figure 3.1.  
Total RNA was purified from rat hybridoma 6C7.1 by using RNeasy mini kit (Qiagen, Germany). 
Cell lysates were homogenized with QIAshredder (Qiagen, Germany). Both kits were used 
according to the manufacturer’s instructions.  
Reverse transcription was performed using SuperScript II reverse transcriptase (RT) (Invitrogen, 
USA). 9 µL total RNA, 2.5 µL oligo(dT)12-18 primer (10 µM) and 5 µL dNTPs were mixed. They were 
incubated for 5 min at 70°C and for 5 min on ice. Afterwards, 5 µL RT buffer (5x), 2.5 µL DTT 
(0.1 M) and 1 µL SuperScript II reverse transcriptase (200 u/µL) were added and incubated for 
60 min at 42°C. The reaction was stopped by incubation for 15 min at 70°C. The generated cDNA 
was stored at -20°C.  
 
AAAAA
TTTTT
AAAAA
TTTTT
AAAAA
VH VL
pelB VH   Yol     VL  myc His
hybridoma
RNA
cDNA
VH and VL genes
pOPE vector
 
 
Fig.  3.1: Isolation of variable gene regions of VCAM-1 specific antibody 6C7.1 
 
After reverse transcription, the VL and VH gene fragments were isolated by PCR. Primer 
NS 21 forward and Bi5 reverse (see Tab. 3.9) were used to amplify the VL fragment that was 
digested with BamHI and EcoRV. The desired VH fragment was amplified using primers Bi3b for 
and Bi4 rev and was digested with HindIII and PstI. The VL and VH fragments were sequentially 
ligated into the E. coli expression vector pOPE101 (Schmiedl et al., 2000) and the plasmid was 
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named pOPE101-scFv6C7.1. It encodes the scFv antibody fragment specific for VCAM-1 that 
contains a C-terminal myc- and His-tag for detection. All cloning steps were verified by DNA 
sequencing.  
 
3.2.11 Generation of mammalian expression vectors 
A mammalian expression vector was constructed that encodes a fusion protein of murine VCAM-1 
(extracellular, transmembrane and cytoplasmic domain) and yellow fluorescent protein (YFP) 
(see Fig. 4.4). The gene of Venus, a modified YFP version, was released from vector pCS-Venus 
(Nagai et al., 2002) using the restriction enzymes NcoI and XbaI. It was ligated into the plasmid 
pCMV/myc/ER (Invitrogen, USA), obtaining the vector pCMV-YFP. The cDNA of murine VCAM-1 
was obtained from plasmid pCMV-Sport6-muVCAM1 (RZPD, Germany) by amplification using 
forward primer NS 5 and reverse primer NS 8. The resulting PCR product was digested with BssHII 
and BglII and ligated into pCMV-YFP. The resulting expression vector was named pCMV-VCAM-
YFP.  
 
The VCAM-1 specific antibody fragment scFv6C7.1 was subcloned into two different mammalian 
expression vectors either containing or lacking the C-terminal ER retention sequence KDEL. 
pCMV-scFv6C7.1 was generated by digestion of pOPE101-scFv6C7.1 with PstI and XbaI and 
ligation of the scFv6C7.1 gene into vector pCMV. To obtain pCMV-scFv6C7.1-KDEL, the DNA 
coding for the amino acids Lys-Asp-Glu-Leu (KDEL) was added to the C-terminus of the antibody 
fragment via PCR.  
Two control constructs were generated that encode the antibody fragment scFv215, which binds to 
RNA polymerase II from Drosophila melanogaster (Liu et al., 1999). The gene fragment encoding 
scFv215 was amplified using the template pOPE101-215(yol) and the oligonucleotides #144 and 
#255. The PCR product was digested with PstI and BglII and was ligated into the vectors pCMV-
scFv6C7.1 and pCMV-scFv6C7.1-KDEL replacing the 6C7.1 inserts. The resulting control antibody 
constructs were named pCMV-scFv215 and pCMV-scFv215-KDEL. An overview of all mammalian 
expression vectors constructed for this study is given in table 3.12.  
 
Tab.  3.12: Mammalian expression vectors used in this study 
plasmid ER retention encoded protein 
pCMV-VCAM-YFP no fusion of VCAM-1 antigen and yellow fluorescent protein (YFP) 
pCMV-scFv6C7.1 no scFv format of VCAM-1 specific antibody 6C7.1 
 
pCMV-scFv6C7.1-KDEL yes scFv format of VCAM-1 specific antibody 6C7.1 
 
pCMV-scFv215 no scFv format of anti-RNA polymerase II of D. melanogaster 
pCMV-scFv215-KDEL yes scFv format of anti-RNA polymerase II of D. melanogaster 
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3.3 Microbiological methods 
3.3.1 Glycerol stocks 
For long-term storage of bacteria, glycerol cultures were used. Therefore, 800 µL freshly cultured 
E. coli cells were mixed with 200 µL of 87% (w/v) glycerol (final concentration of 30% (w/v) 
glycerol). The suspensions were stored at -80°C.  
 
3.3.2 Chemically competent cells 
An overnight culture of E. coli XL-1 blue cells was used to inoculate 50 mL of 2xYT-T medium. The 
bacteria were incubated at 37°C and 250 rpm until the culture reached an OD600nm of 0.4. The cells 
were harvested by centrifugation (3220 x g, 10 min, 4°C) and were resuspended in 7.5 mL of ice-
cold 100 mM CaCl2. After centrifugation (3220 x g, 10 min, 4°C), the cells were resuspended in 
1 mL of ice-cold 100 mM CaCl2. After 1 h on ice, 1 mL cold 40% (v/v) glycerol in 100 mM CaCl2 
was added. Competent cells were separated into 150 µL portions, shock frozen and stored  
at -80°C.  
 
3.3.3 Transformation of E. coli 
Chemically competent E. coli cells were transformed by heat shock. DNA was mixed with 50 µL of 
E. coli cells and was placed on ice for 20 min. After heating the cells for 45 sec to 42°C, the cells 
were cooled down on ice for 2 min. To regenerate the transformed cells, they were incubated in 
500 µL of SOC medium at 37°C with shaking for 1 h. The cells were plated on a 2xYT agar plate 
with appropriate antibiotics. The plate was incubated overnight at 37°C. 
 
3.3.4 Production of antibody fragments in E. coli XL-1 blue  
Antibody fragments (scFvs) were produced in microtiter plates. Briefly, 140 µL 2xYT-GA medium 
were inoculated with 10 µL overnight culture. Incubation was performed at 37°C and 1400 rpm 
using a microtiter plate shaker. When the OD600nm reached a value of 0.5, the microtiter plate was 
centrifuged (5 min at 3220 x g) and the supernatants were discarded. To induce the expression of 
the antibody genes, the pellets were resuspended in 150 µL 2xYT-A with 50 µM IPTG and were 
incubated overnight at 30°C and 1400 rpm. Cells were separated from the antibody containing 
supernatant by centrifugation for 5 min at 3220 x g.  
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3.4 Biochemical methods 
3.4.1 Purification of antibodies with protein G 
A protein G column (1 mL HiTrap Protein G HP, GE Healthcare, USA) was used for purification of 
rat IgG1 antibodies with affinity chromatography in an Äkta prime system. Protein G is a cell 
surface protein of Group G streptococci and is a Type III Fc receptor that binds to the Fc region of 
IgGs. Unlike protein A, it also binds to rat IgGs.  
All buffers and the distilled water were filtered (0.45 µm), degassed and pre-chilled to 4°C. The cell 
culture medium containing the antibodies was centrifuged at maximum speed for 10 min at 4°C and 
was filtered as well.  
To prepare the protein G column, it was washed with water and was equilibrated with binding buffer 
(pH 7.0). Afterwards, the filtered cell culture medium was loaded onto the column with a flow rate of 
0.4 mL/min overnight. The column was washed with binding buffer and the bound antibodies were 
eluted with elution buffer (pH 2.7). To protect the eluted antibodies, 1 mL fractions were collected 
into tubes containing 100 µL neutralization buffer (pH 9.0). Therefore, the elution fractions had a 
neutral pH value. All buffers and solutions used for purification of antibodies with protein G are 
listed in chapter 3.1.4.  
 
3.4.2 Determination of protein concentration 
Protein concentrations were determined using the colorimetric method developed by Bradford 
(Bradford, 1976). A 96-well MaxiSorp plate was filled with 75 µL of a BSA dilution series 
(1-100 µg/mL) or 75 µL of a dilution series of the protein sample. Bradford reagent (5x, Bio-Rad, 
Germany) was diluted in water. 75 µL of diluted Bradford reagent were added to each well and 
incubated for 20 min at room temperature. The absorbance at 595 nm was measured in a TECAN 
reader. A standard curve was set up based on a BSA standard and the protein concentrations of 
the samples were calculated according to this curve.  
 
3.4.3 SDS-PAGE 
Sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) was used to separate 
proteins according to their electrophoretic mobility. The running and stacking gel were cast 
according to table 3.13. The running gel was prepared and overlaid with isopropanol. After gel 
polymerization, the isopropanol was removed, the stacking gel was cast and a comb was inserted.  
Tab.  3.13: Recipe for SDS-PAGE 
 Stacking gel 
(4%) 
Running gel 
(12%) 
dH2O 1.0 mL 1.3 mL 
30% Acrylamide mix  0.26 mL 1.6 mL 
1.5 M Tris-HCl (pH 8.8) - 1.0 mL 
1 M Tris-HCl (pH 6.8) 0.20 mL - 
10% (w/v) SDS 15 µL 40 µL 
10% (w/v) APS 15 µL 40 µL 
TEMED 2 µL 2 µL 
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The protein samples were mixed with Laemmli’s sample buffer and were boiled for 10 min at 96°C. 
Afterwards the Precision Plus protein standard (Bio-Rad, Germany) and the appropriate samples 
were loaded onto the gel. Electrophoresis was performed with maximal voltage and 20 mA per gel. 
All buffers and solutions used for SDS-PAGE are listed in chapter 3.1.4.  
 
3.4.4 Coomassie staining 
Proteins on SDS-gels were stained with Coomassie staining solution (chapter 3.1.4). To destain 
the gels, destaining solution (chapter 3.1.4) was applied until the protein bands were clearly visible.  
 
3.4.5 Western blot 
A semi-dry Western blot was performed to transfer proteins from SDS gels onto polyvinylidene 
fluoride (PVDF) membranes. Blotting paper was soaked in blotting buffer (chapter 3.1.4) and put 
onto the transfer cell. After activating the PVDF membrane with methanol, it was placed on the 
blotting paper. The SDS gel was laid on top and was covered with soaked blotting paper. Transfer 
of the proteins was performed at 20 V for 45 min.  
 
3.4.6 Immunostain 
After Western blotting, the membrane was blocked with PBS/BSA for 30 min at room temperature 
to limit unspecific binding of the detection antibodies, and was washed with PBS. Detection was 
performed either directly via AP-conjugated antibody or indirectly via specific primary antibody 
followed by AP-conjugated secondary antibody. The appropriate antibodies are summarized in 
table 3.14. They were diluted in PBS/BSA and were incubated for 1 h at room temperature. After 
washing with PBS and substrate buffer, bound antibodies were visualized in NBT/BCIP (NBT and 
BCIP solution 1:100 in substrate buffer). Finally, the membrane was washed with water and was 
dried. All buffers and solutions used for immunostaining are listed in chapter 3.1.4.  
 
Tab.  3.14: Antibodies used for immunostains 
 Direct staining 
of rat IgGs  
 Indirect staining of 
His-tag 
Indirect staining of 
myc-tag 
1st 
antibody 
mouse anti-His5  
(1:2000) 
mouse anti-myc (9E10)  
(1:400) 
antibody anti-rat IgG – AP (1:10000) 2nd 
antibody 
goat anti-mouse IgG 
(Fab-specific) - AP 
(1:5000) 
goat anti-mouse IgG 
(Fab-specific) - AP 
(1:5000) 
 
 
3.4.7 ELISA 
Nunc MaxiSorp microtiter plates were coated with 100 ng recombinant murine VCAM-1 antigen 
(mVCAM1-hum.Fc-His) or 100 ng BSA in 100 µL coating buffer per well at 4°C overnight. The plate 
was washed three times with PBS-T using an ELISA washer and was blocked with 100 µL 
PBS/FCS per well for 1 h at 37°C. Following washing, 50 µL medium containing the scFv6C7.1 and 
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50 µL PBS/FCS were mixed, added to the wells and incubated for 1 h at 37°C. After three 
subsequent washing steps, the primary detection antibody mouse anti-(c)myc (9E10, 1:10 in 
PBS/FCS) was added and incubated for 1 h at 37°C. Afterwards the plates were washed again. 
Goat anti-mouse IgG (Fab-specific) antibody conjugated with horse radish peroxidase (HRP, 
1:10000) was used as secondary detection antibody and was incubated for 1 h at 37°C. Unbound 
antibodies were removed by additional washing steps. Bound antibodies were visualized with TMB 
substrate (TMB solution A and B were mixed in a ratio of 21:1). After stopping the reaction by 
adding 100 µL stopping solution, absorbance at 450 nm was measured in an ELISA reader. All 
buffers and solutions used for ELISA are listed in chapter 3.1.4.  
 
3.4.8 Surface plasmon resonance 
Surface plasmon resonance (SPR) was performed using the sensor chip CM5 and a Biacore2000 
(GE Healthcare, USA). The matrix of the chip is a carboxymethylated dextran covalently attached 
to a gold surface. Molecules can be covalently coupled to the sensor surface via amino groups. 
Therefore, the CM5 chip was equilibrated with PBST first. Afterwards, the dextran matrix was 
activated with a mixture of EDC and NHS (ratio 1:1).  
Murine VCAM-1 antigen (mVCAM1-hum.Fc-His, 1 µg/mL at pH 4.5) was coupled to flow cell 4 by 
using a flow rate of 10 µL/min for 2 min. Reference flow cell 3 was immobilized with BSA (2 µg/mL 
at pH 4.5) at 10 µL/min for 2 min. The remaining reactive amino groups of the sensor chip were 
saturated with ethanolamine. All buffers and solutions used for SPR are listed in chapter 3.1.4.  
To determine whether both VCAM-1 specific antibodies sterically interfere during antigen binding, 
they were sequentially injected. Antibody 6C7.1 was injected first, followed by antibody 6434. Both 
antibodies were used in IgG form to exclude any influences of the antibody format. They were 
applied at a concentration of 75 µg/mL in PBST with a flow rate of 20 µL/min for 4 min.  
 
 
3.5 Cellular and immunological methods 
3.5.1 Cell culture conditions 
The adherent cell lines HEK-293 and HEK-293T were cultured in DMEM medium containing 
4.5 g/L glucose, supplemented with 8% FCS and 100 µg/mL penicillin/streptomycin. They were 
incubated at 37°C, 7% CO2 and a humidity of 96%. To passage them, they were washed with PBS 
and were incubated with trypsin/EDTA until they detached from the tissue culture plates. The cells 
were seeded onto fresh plates containing 10 mL of medium that was preheated to 37°C.  
The rat hybridoma 6C7.1 was grown in serum-free ISF medium. Jurkat, a human acute T cell 
leukemia cell line was maintained in RPMI 1640 medium containing 10% FCS and 100 µg/mL 
penicillin/streptomycin. Hybridoma and Jurkat cells were incubated at 37°C in a humidified 
atmosphere containing 5% CO2. Both suspension cell lines were counted (see chapter 3.5.3) and 
were subcultured every second day. 
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3.5.2 Freezing and thawing of cells 
For long-term storage, the cells were harvested as described above. They were centrifuged and 
resuspended in freezing medium (10% DMSO and 20% FCS in medium) and were transferred into 
cryo tubes. To allow a slow and gradual freezing, the tubes were stored at -80°C in a closed 
styrofoam container for one day. Afterwards, the tubes were transferred to liquid nitrogen.  
For thawing, frozen cells were incubated in a 37°C water bath and were seeded in appropriate cell 
culture medium.  
 
3.5.3 Counting cells 
To distinguish between living and dead cells, single cell suspensions were mixed with trypan blue, 
a dye that only stains dead cells. Living and dead cells were counted in a hemocytometer. Finally, 
the cell density (cells/mL), the total number of cells and the percentage of living cells were 
calculated.  
 
3.5.4 Transient and stable transfection 
Cells were transiently transfected using either lipofection via HEKfectin or magnetofection via 
NeuroMag according to the suppliers’ instructions. The used amounts of DNA and appropriate 
transfection reagent are shown in table 3.15.  
Tab.  3.15: Transfections 
Reagent Supplier (Cat. Nr.) 6-well 10 cm plate 
 
 
DNA [µg] Reagent [µL] DNA [µg] Reagent [µL] 
HEKfectin Bio-Rad  (170-3381) 2 10 10 40 
NeuroMag OzBiosciences (NM50200) 4 14 12 42 
 
HEK-293 cells were stably transfected using HEKfectin. Cells were selected in DMEM medium 
containing 4.5 g/L glucose, supplemented with 8% (v/v) FCS, 100 µg/mL penicillin/streptomycin 
and 0.4 mg/mL G-418.  
 
3.5.5 Lysis of mammalian cells 
Mammalian cells were washed with pre-chilled PBS and were centrifuged at 300 x g for 5 min. 
Lysis buffer (chapter 3.1.4) was freshly supplemented with protease inhibitors (listed in table 3.16). 
200 µL lysis buffer were added to each cell sample and the mixture was incubated for 30 min on 
ice. Afterwards, the lysed cells were centrifuged at 12000 rpm for 10 min at 4°C. The supernatants 
were transferred into fresh reaction tubes and were stored at –20°C.  
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Tab.  3.16: Protease inhibitors 
Protease 
inhibitor 
Protease target Stock solution Working 
concentration 
Aprotinin Serine protease 
 
1 mg/mL in PBS 5 µg/mL 
Leupeptin Serine and 
cysteine protease 
1 mg/mL in H2O 5 µg/mL 
Pepstatin Acid protease 
 
1 mg/mL in 
methanol 
5 µg/mL 
EDTA Metalloprotease 
 
0.5 M in H2O pH 
8.0 
0.5 - 2 mM 
PMSF Serine protease 100 mM in 
Isopropanol 
1 mM 
 
 
3.5.6 Flow cytometry 
Adherent cells were washed with PBS and were detached with trypsin/EDTA. The cells were 
resuspended in medium and were counted in a hemocytometer. A total of 1 x 105 cells were 
transferred into 5 mL tubes. 3.5 mL buffer A (chapter 3.1.4) was added and the cells were 
centrifuged at 300 x g for 5 min at 4°C.  
For intracellular stainings cells were fixed in 150 µL 2% (v/v) Formaldehyde for 15 min and were 
permeabilized with 150 µL buffer B (chapter 3.1.4) for another 15 min. In order to stain cells 
extracellularly, they were neither fixed nor permeabilized.  
In different experiments cells were either stained for surface VCAM-1 or the His-tag was detected 
intra-/extracellularly. The appropriate procedures used are summarized in table 3.17. In all cases, 
the cell pellet was resuspended in 100 µL of primary antibody and incubated for 1 h. Afterwards 
cells were washed twice with buffer A and were incubated in 100 µL of secondary antibody for 
30 min. After two washing steps with buffer A, cells were resuspended in 500 µL buffer A and were 
analyzed by flow cytometry using a Beckman Coulter FC500 with two lasers (488 nm and 633 nm). 
For each sample 104 events were collected and data were analyzed using Beckman Coulter CXP 
analysis software.  
 
Tab.  3.17: Staining procedures for flow cytometry 
 Surface staining of 
VCAM-1 (extracellular) 
Surface staining of  
His-tag 
(extracellular) 
Staining of His-tag 
(intracellular) 
Fixation 
 
no no yes 
Permeabilization 
 
no no yes 
1st antibody 
 
rat anti-VCAM-1 (6434) 
(10 µg per tube 
in buffer A) 
mouse anti-His6  
(1:50 in buffer A) 
mouse anti-His6  
(1:50 in buffer B) 
2nd antibody 
 
goat anti-rat IgG F(ab’)2 
fragment - APC 
(1:100 in buffer A) 
goat anti-mouse IgG-
PE  
(1:100 in buffer A) 
goat anti-mouse IgG-
PE  
(1:100 in buffer B) 
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3.5.7 Fluorescence microscopy 
Cells were grown on sterile, poly-L-lysine coated cover slips. After rinsing the cells with PBS, they 
were fixed in 3.7% (v/v) formaldehyde for 15 min at room temperature (rt). For intracellular staining, 
cells were permeabilized with 0.1% (v/v) Triton X-100 in PBS for 4 min at rt and cells were 
incubated with blocking buffer (chapter 3.1.4) for 30 min at rt.  
For VCAM-1 surface staining, VCAM-1 specific rat antibody 6434 (R&D Systems, USA, 1:100 in 
blocking buffer) was used as primary antibody and was incubated for 1 h at rt. Afterwards, the cells 
were stained with TRITC-conjugated goat anti-rat IgG (H+L) (Rockland, USA, 1:400 in blocking 
buffer) for 30 min at rt. For intracellular staining of the His-tag, permeabilized cells were incubated 
with mouse anti-His6 antibody (Roche, Germany, 1:100 in blocking buffer) followed by goat anti-
mouse Alexa Fluor 546 antibody (Invitrogen, USA, 1:200 in blocking buffer) for 1 h at rt. The nuclei 
of cells were counterstained with DAPI (1:2000 in H2O) for 5 min at rt. All intermediate washing 
steps were performed three times with PBS. A final washing step with water was performed and 
the cells were mounted in Mowiol (Calbiochem, Merck, Germany).  
An Axiovert 200 (Carl Zeiss, Germany) was used for fluorescence microscopy. Confocal laser 
scanning microscopy was performed with an LSM 510META (Carl Zeiss, Germany). All images 
were analyzed with LSM Image browser (Carl Zeiss, Germany) and ImageJ (National Institutes of 
Health, USA). To calculate the Manders’ overlap coefficients, the JACoP plug in (Bolte et al., 2006) 
was integrated into the latter program. 
 
Tab.  3.18: Staining procedures for fluorescence microscopy 
 Surface staining of VCAM-1 
(extracellular) 
Staining of His-tag 
(intracellular) 
Fixation 
 
yes yes 
Permeabilization 
 
no yes 
1st antibody rat anti-VCAM-1 (6434) (1:100 in blocking buffer) 
mouse anti-His6  
(1:100 in blocking buffer) 
2nd antibody goat anti-rat IgG (H+L) - TRITC (1:400 in blocking buffer) 
goat anti-mouse - AlexaFluor546 
(1:200 in blocking buffer) 
 
 
3.5.8 Cell-cell adhesion assay with Jurkat cells 
Cells were cultured on poly-L-lysine coated cover slips. HEK-293:VCAM-YFP cells were used as 
positive control (VCAM-1surface+), HEK-293 cells as negative control (VCAM-1surface-).  
For fluorescence microscopy, Jurkat cells were labeled with the red membrane dye Cell Tracker 
CM Dil (Molecular Probes, Invitrogen, USA). Briefly, Jurkat cells were centrifuged at 300 x g for 
5 min. After washing them twice with preheated D-PBS (chapter 3.1.4), the cells were resuspended 
in 1 mL 1 µM CM Dil in D-PBS and incubated for 5 min at 37°C and for 15 min at 4°C. After two 
washing steps with preheated PBS, the labeled Jurkat cells were diluted in prewarmed RPMI 
medium. 
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A total of 9 x 103 Jurkat cells were given onto the adherent cells and the mixture was incubated for 
10 min at 37°C. The cells were fixed in 3.7% (v/v) formaldehyde and were incubated for 10 min at 
37°C. After washing with water, the cells were mounted in Mowiol and analyzed by fluorescence 
microscopy. 
 
3.5.9 Transfer assay 
Adherent HEK-293:VCAM-YFP cells were transiently transfected with antibody constructs using 
lipofection and the medium was changed 24 h after transfection. The cells were cultured with fresh 
medium for another 24 h and it was harvested afterwards. First centrifugation was carried out at 
300 x g for 5 min and the supernatants were transferred into fresh tubes. Second centrifugation 
was done at 16000 x g for 10 min and the supernatants were analyzed by Western blot and ELISA.  
1.5 mL of the medium was transferred to fresh HEK-293:VCAM-YFP cells cultured on cover slips. 
The cells were incubated overnight and an adhesion assay with unlabeled Jurkat cells was 
performed as described before (chapter 3.5.8). The transfected HEK-293:VCAM-YFP cells were 
harvested with trypsin/EDTA and were lysed following the procedure depicted in chapter 3.5.5. 
Intracellular and medium fractions were analyzed by immunoblot and ELISA.  
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4 Results  
4.1 Production and purification of VCAM-1 specific antibody 6C7.1 
The monoclonal VCAM-1 specific antibody 6C7.1 (rat IgG1) was produced and purified in order to 
compare its specificity to the commercial VCAM-1 specific antibody 6434 (rat IgG1), which was 
used as detection antibody for VCAM-1 in later experiments. Therefore, hybridoma 6C7.1 
(Engelhardt et al., 1998) was grown in serum-free ISF medium and the antibody was purified using 
protein G. All elution fractions, the flow-through of the purification and the unpurified cultured 
medium were analyzed by SDS-PAGE followed by Coomassie staining or immunoblot.  
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Fig.  4.1: Purification of VCAM-1 specific antibody 6C7.1 (IgG format) 
SDS-PAGE followed by Coomassie staining (A) or immunoblot (B). Detection was performed 
with AP-conjugated anti-rat IgG antibody. F2 – F12: elution fraction 2 to 12 from purification 
via protein G; flow-through 1 and 2: flow-through of protein G column; cultured medium: 
medium before purification via protein G. The heavy chain (HC) and the light chain (LC) of 
the detected rat antibody are highlighted by arrows.  
 
The Coomassie-stained SDS gel (Fig. 4.1 A) and the immunoblot (Fig. 4.1 B) revealed protein 
bands of approximately 25 and 50 kDa in the elution fractions, corresponding to the light and heavy 
chains of IgG molecules. The flow-through fractions and the unpurified culture medium showed 
additional proteins, which were only detectable by Coomassie staining. These might be either host 
cell proteins or various proteins from the culture medium. Fractions F4 to F7 (higher concentration 
of antibody) and F8 to F12 (lower concentration of antibody) were pooled. A Bradford assay was 
performed and protein concentrations of 0.4 µg/µL and 0.15 µg/µL were determined, respectively.  
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4.2 VCAM-1 specific antibodies 6C7.1 and 6434 do not sterically interfere 
To analyze differences in surface expression of a molecule targeted by an intrabody construct, the 
detection system has to recognize a non-overlapping epitope. Surface plasmon resonance (SPR) 
was used to test this for the VCAM-1 specific monoclonal antibodies 6C7.1 and 6434. As shown by 
the sensogram (Fig. 4.2), detection antibody 6434 bound to the antigen in the presence of antibody 
6C7.1. Hence, both antibodies do not sterically interfere during antigen binding. Therefore, 
antibody 6434 is suitable for surface detection of VCAM-1 independently from any bound antibody 
6C7.1.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig.  4.2: Surface plasmon resonance of VCAM-1 specific antibodies 6C7.1 and 6434 
Murine VCAM-1 antigen was coupled to a CM5 chip and the VCAM-1 specific antibodies 
6C7.1 and 6434 were sequentially injected. The reference flow cell was coupled with BSA. 
 
 
 
4.3 Construction and expression of VCAM-1 specific antibody fragment in E. coli  
The variable regions of the VCAM-1 specific antibody 6C7.1 were isolated and cloned into an 
E. coli expression vector. The antibody fragment scFv6C7.1 was produced in microtiter plates and 
the cultivation medium containing the antibody was analyzed by immunoblot and ELISA.  
The scFv fragment had the expected relative molecular mass of about 29 kDa when analyzed by 
SDS-PAGE and immunoblotting (Fig. 4.3 A). Specific binding of the scFv fragment to recombinant 
murine VCAM-1 antigen was verified by ELISA (Fig. 4.3 B).  
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Fig.  4.3: Analysis of antibody fragment scFv6C7.1 produced in E. coli  
Antibody fragment scFv6C7.1 was analyzed by SDS-PAGE followed by immunoblot and 
detection was performed via His-tag (A). Antibody fragment scFv6C7.1 was analyzed by 
antigen ELISA and detection was achieved via myc-tag (B).  
 
 
 
4.4 Knockdown of VCAM-1 by co-expression of VCAM-YFP and ER-retained 
intrabodies 
The VCAM-1 specific antibody fragment scFv6C7.1 was subcloned into two different mammalian 
expression vectors either containing or lacking the C-terminal KDEL-sequence. KDEL is a retention 
sequence for the endoplasmic reticulum (ER), so proteins containing KDEL are retained in the 
lumen of the ER (Munro et al., 1987). Analogously, two control constructs were generated using 
the antibody fragment scFv215 that binds to RNA polymerase II from D. melanogaster (Tab. 3.12).  
 
The antigen VCAM-1 and yellow fluorescent protein (YFP) were genetically fused. When cells were 
transfected with the appropriate gene construct, the fusion protein VCAM-YFP was incorporated 
into the cell membrane (Fig. 4.4). The N-terminal VCAM-1 part of the transmembrane protein was 
expected to localize extracellularly whereas the C-terminal part of VCAM-1 antigen and YFP should 
be located intracellularly. Therefore, all cells transfected with the fusion construct are expected to 
be positive for surface VCAM-1 and YFP fluorescence in parallel.  
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tmVCAM-1 YFPN C
 
Fig.  4.4: Construction of the fusion protein VCAM-YFP  
The extracellular, transmembrane (tm) and intracellular domains of VCAM-1 antigen are 
genetically fused to C-terminal yellow fluorescent protein (YFP). Subsequently, cells are 
transfected with the resulting construct VCAM-YFP.  
 
 
HEK-293T cells were transiently transfected with the fusion construct VCAM-YFP and the following 
four different antibody constructs: the VCAM-1 specific antibody construct scFv6C7.1 with or 
without KDEL and the control antibody construct scFv215 with or without the KDEL-sequence, 
respectively. The VCAM-1 overall expression was determined by fluorescence measurement of 
VCAM-YFP. Cell surface levels of VCAM-1 were analyzed by extracellular staining of VCAM-1 to 
study the VCAM-1 surface knockdown.  
 
Flow cytometry analysis revealed that untransfected HEK-293T cells were negative for YFP and 
surface VCAM-1 as expected (Fig. 4.5 B, neg. control). Cells transiently transfected with the 
VCAM-YFP fusion protein expressed high levels of VCAM-1 on their surface, indicated by the 
double fluorescent (YFP+ VCAM-1surface+) cell population located in the upper right quadrant of the 
dot plot (Fig. 4.5 D). Co-transfection of VCAM-YFP and ER-retained knockdown construct 
scFv6C7.1-KDEL resulted in a shift of the double fluorescent (YFP+ VCAM-1surface+) cell population 
to the single fluorescent (YFP+ VCAM-1surface-) cell population in the lower right quadrant 
(Fig. 4.5 F). This disappearance of surface fluorescence could not be attributed to a sterical 
blocking of the epitope recognized by the detection antibody 6434, because it has been shown in 
figure 4.2 that the antibodies 6C7.1 and 6434 do not sterically interfere.  
 
According to these results, co-expression of VCAM-YFP antigen and intrabody construct led to a 
specific and nearly complete knockdown of VCAM-1 surface antigen. Co-transfection of VCAM-
YFP and the control antibody constructs scFv6C7.1, scFv215-KDEL or scFv215 led to cells that 
were positive for surface VCAM-1 (Fig. 4.5 H, J and L). Cells transfected with the knockdown 
intrabody scFv6C7.1-KDEL alone (Fig. 4.5 N, neg. control) neither showed any YFP expression nor 
any VCAM-1 surface expression as expected.  
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Fig.  4.5: Flow cytometry of cells co-transfected with antigen and antibody fragments 
HEK-293T cells were transiently transfected with VCAM-YFP and antibody constructs 
indicated using lipofection with HEKfectin. 24 h after transfection cells were stained for 
VCAM-1 surface expression (B, D, F, H, J, L and N). Cells stained with secondary antibody 
alone were used as control (A, C, E, G, I, K and M).  
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4.5 Generation of a cell line stably expressing VCAM-YFP fusion protein 
Transient co-transfection of antigen and knockdown intrabody constructs may not reflect the 
physiological situation for studying protein function, because the expression of antigen and antibody 
start at the same time. Therefore, HEK-293 cells were stably transfected with plasmid pCMV-
VCAM-YFP to generate the cell clone HEK-293:VCAM-YFP.  
The VCAM-YFP fusion protein predominantly localized at the cell surface (Fig. 4.6 A). In addition, 
surface expression of VCAM-YFP protein was verified by surface staining of VCAM-1 (Fig. 4.6 B). 
The appropriate overlay is shown in figure 4.6 C.  
 
A                         C 
B
 
Fig.  4.6: Generation of the stable cell line HEK-293:VCAM-YFP 
HEK-293 cells were stably transfected with pCMV-VCAM-YFP using lipofection. Detection of 
VCAM-YFP fusion protein (A), VCAM-1 surface expression detected by extracellular staining 
of VCAM-1 (B), overlay of both (C). 
 
 
 
4.6 Intracellular and extracellular detection of antibody fragments via His-tag 
In order to analyze the expression of antibody fragments, HEK-293:VCAM-YFP cells were 
transiently transfected with four different plasmids encoding secreted or intracellular antibody 
fragments. Two days after transfection, the antibody fragments were detected via their His-tags 
intra- or extracellularly. All cells were analyzed using flow cytometry.  
Untransfected HEK-293:VCAM-YFP cells were negative for intracellular and surface His-tag as 
expected (Fig. 4.7 A and B). 88% of cells transfected with the ER-retained knockdown construct 
scFv6C7.1-KDEL were positive for intracellular His-tag (Fig. 4.7 C). After extracellular staining of 
the His-tag, 85% of cells were positive (Fig. 4.7 D). These results were not expected at all and will 
be discussed in chapter 5. After transfection with the secreted construct scFv6C7.1 (without 
KDEL), 81% of cells were positive for intracellular His-tag (Fig. 4.7 E). Extracellular staining of 
these cells revealed that 91% were positive for His-tag (Fig. 4.7 F). These results will also be 
mentioned in the discussion.  
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Cells transfected with the control constructs scFv215-KDEL and scFv215 were positive for 
intracellular His-tags (Fig. 4.7 G and I). The transfected antibody constructs were expressed by 
53% and 51% of cells, respectively. Therefore, the overall transfection efficiency of HEK-
293:VCAM-YFP cells can be estimated to be about 51 to 53%. HEK-293:VCAM-YFP cells 
transfected with control constructs did not show any His-tag levels on their cell surface as expected 
(Fig. 4.7 H and J).  
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Fig.  4.7: Flow cytometry of cells transfected with antibody constructs (staining of His-tag) 
HEK-293:VCAM-YFP cells were transiently transfected with four different antibody constructs 
using lipofection (C-J). Untransfected HEK-293:VCAM-YFP cells were used as negative control 
(A, B). 48 h after transfection, expressed scFvs were detected via intracellular or extracellular 
staining of the His-tag (black). Cells stained with secondary antibody alone were used as control 
(grey).  
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4.7 Surface knockdown of VCAM-1 is time dependent  
HEK-293:VCAM-YFP cells were transiently transfected with the four different antibody constructs 
indicated. Untransfected HEK-293:VCAM-YFP cells expressed high levels of VCAM-1 on their cell 
surface (Fig. 4.8 B and C). After transfection with the ER-retained knockdown construct scFv6C7.1-
KDEL, the VCAM-1surface+ cell population (upper right quadrant) was reduced, whereas the 
VCAM-1surface- cell population simultaneously increased over time (lower right quadrant, highlighted 
by a red circle) (Fig. 4.8 E and F). This effect was already detectable 48 h after transfection, but 
became even stronger 96 h post transfection. Cells transfected with the secreted construct 
scFv6C7.1 without KDEL did not downregulate their VCAM-1 surface levels as expected 
(Fig. 4.8 H and I). Finally, cells were transfected with control antibody scFv215 containing or 
lacking the KDEL-sequence (Fig. 4.8 K, L, N and O). 48 h after transfection, both constructs led to 
a marginal decrease in surface VCAM-1 expression (Fig. 4.8 K and N). This unspecific effect could 
be related to the expression of the antibody fragment scFv215 and will be discussed in chapter 5.  
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Fig.  4.8: Flow cytometry of cells transfected with antibody constructs (staining of VCAM-1) 
HEK-293:VCAM-YFP cells were transiently transfected with four different antibody constructs using lipofection 
(D-O). Untransfected HEK-293:VCAM-YFP cells were used as negative control (A-C). 48 h and 96 h after 
transfection, cells were stained for VCAM-1 surface expression. Cells stained with secondary antibody alone 
were used as control (A, D, G, J, M). Cell populations of interest are highlighted by red circles.  
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The average transfection efficiency of HEK-293:VCAM-YFP cells is approximately 52% (see 
chapter 4.6). Based on this finding, the percentage of cells that are knocked down for VCAM-1 
surface expression can be calculated from the flow cytometry data.  
 
 
 
 
 
 
 
 
 
Fig.  4.9: Knockdown efficiency in flow cytometry (48 and 96 h after transfection) 
Percentages of cells with a knockdown of VCAM-1 surface expression were calculated from 
flow cytometry data (Fig. 4.8) based on the average transfection efficiency of 52%. 
 
 
For untransfected cells or cells transfected with control antibodies, the calculated VCAM-1 
knockdowns ranged from 1% to 16%. For cells transfected with knockdown intrabody construct 
scFv6C7.1-KDEL, 43% of transfected cells lost their VCAM-1 surface expression 48 h after 
transfection (Fig. 4.9, grey bar). 96 h after transfection, this number increased to 94% 
(Fig. 4.9, black bar), demonstrating the time-dependency of the VCAM-1 surface knockdown by 
ER-retained intrabodies.  
 
 
 
4.8 VCAM-1 surface knockdown can be visualized by immunofluorescence 
In parallel to flow cytometry, immunofluorescence was performed to visualize the knockdown of 
surface VCAM-1 mediated by co-expression of ER-retained intrabodies. HEK-293:VCAM-YFP cells 
were transiently transfected with the antibody constructs indicated.  
Untransfected HEK-293:VCAM-YFP cells were analyzed as negative control and showed VCAM-1 
surface expression (Fig. 4.10 A). VCAM-YFP fusion antigen was detected both on the surface and 
inside the cells (Fig. 4.10 B). Cells were also transfected with knockdown intrabody construct 
scFv6C7.1-KDEL (Fig. 4.10 D-F). Only the right of the two cells shown exhibited VCAM-1 surface 
expression, whereas the left one was not, indicating VCAM-1 surface knockdown in this cell 
(Fig. 4.10 D, arrow). However, both cells expressed the VCAM-YFP fusion protein intracellularly 
(Fig. 4.10 E). The overlay indicates that the left cell lacked VCAM-1 surface expression, but still 
showed VCAM-YFP intracellularly (Fig. 4.10 F, arrow). Whenever observed, the knockdown 
appeared to be fairly complete. According to the transfection efficiency of approximately 52%, it is 
likely that the right cell shown was not transfected with the knockdown construct and consequently 
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expressed VCAM-1 on its cell surface. Transfection of cells with any of the control constructs did 
not influence the surface distribution of VCAM-1 (Fig. 4.10 G-O). 
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Fig.  4.10: Immunofluorescence of cells transfected with antibody constructs 
HEK-293:VCAM-YFP cells were transiently transfected with the four different antibody 
constructs using lipofection (D-O). Untransfected HEK-293:VCAM-YFP cells were used as 
negative control (A-C). Surface VCAM-1 was stained 48 h after transfection (A, D, G, J, and 
M). 
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To determine the percentages of cells with downregulated VCAM-1 surface expression, the 
immunofluorescence results were quantified visually (Fig. 4.11). Therefore, the number of cells 
identified by their nuclear staining in the DAPI channel was counted and set to n. Cells positive for 
VCAM-1 surface staining (TRITC channel, red fluorescence) and positive for VCAM-YFP 
expression (FITC channel, green fluorescence) were counted. The percentages of cells knocked 
down for VCAM-1 surface expression were calculated considering the previously determined 
transfection efficiency of 52%.  
 
 
 
 
 
 
 
 
 
 
 
Fig.  4.11: Knockdown efficiency in immunofluorescence 
HEK-293:VCAM-YFP cells were transiently transfected with plasmids encoding knockdown 
or control antibody constructs using lipofection. Untransfected HEK-293:VCAM-YFP cells 
were used as negative control. 48 h after transfection, cells were stained for surface 
VCAM-1.  
 
 
It was calculated that 57% of cells transfected with the ER-retained knockdown construct 
scFv6C7.1-KDEL showed a downregulation of surface VCAM-1. In contrast, only 6% of cells 
transfected with the secreted control construct scFv-6C7.1 had a reduced level of surface VCAM-1. 
Analogously, untransfected HEK-293-VCAM-YFP cells did not show any VCAM-1 downregulation.  
For cells transfected with control constructs scFv215 containing or lacking the sequence KDEL, 
24% and 26% were calculated to be knocked down for surface VCAM-1, respectively. These 
surprisingly high percentages will be discussed in chapter 5.  
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4.9 Knockdown of surface VCAM-1 abolishes cell-cell adhesion 
To evaluate the influence of VCAM-1 specific intrabodies on the function of VCAM-1, a cell-cell 
adhesion assay was established using Jurkat cells. These cells endogenously express VLA-4, a 
α4β1 integrin that is the physiological interaction partner of VCAM-1. Two independent experiments 
were performed, one with unlabeled Jurkat cells (Fig. 4.12 A1-F1) and another one with Jurkat cells 
labeled with a red fluorescent membrane dye for better discrimination (Fig. 4.12 A2-F2).  
 
 
Fig.  4.12: Cell-cell adhesion assay for VCAM-1 function 
HEK-293:VCAM-YFP cells (green) were transiently transfected using lipofection and 48 h later, they were 
incubated with unlabeled (A1-F1) or labeled (A2-F2) Jurkat cells (red). Formation of aggregates was analyzed 
by fluorescence microscopy: untransfected HEK-293:VCAM-YFP cells (A1, positive control; A2, fluorescence; 
A3, DIC microscopy), untransfected HEK-293 cells (B1, negative control), HEK-293:VCAM-YFP cells 
transfected with knockdown intrabody construct scFv6C7.1-KDEL (C1, C2), control constructs scFv215-KDEL 
(D1, D2), scFv6C7.1 (E1, E2) or scFv215 (F1, F2). 
 
 
Jurkat cells bound well to HEK-293:VCAM-YFP cells and formed characteristic “berry-like” clusters 
(Fig. 4.12 A1, positive control), which were detectable in fluorescence (Fig. 4.12 A2) and differential 
interference contrast (DIC) microscopy (Fig. 4.12 A3). VCAM-1 negative HEK-293 cells did not 
form any aggregates with Jurkat cells (Fig. 4.12 B1, negative control), indicating that the binding of 
Jurkat cells is based on the interaction of VCAM-1 and VLA-4. HEK-293:VCAM-YFP cells 
transfected with the ER-retained intrabody knockdown construct scFv6C7.1-KDEL did not 
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efficiently bind Jurkat cells (Fig. 4.12 C1, C2). The formation of clusters was strongly impaired, 
proving effective functional VCAM-1 surface knockdown.  
Cells transfected with control intrabody scFv215-KDEL showed a clear binding to Jurkat cells and 
formation of clusters (Fig. 4.12 D1 and D2, see arrows). Therefore, surface expression of VCAM-1 
antigen seems not to be affected by overexpression of control intrabodies. Cells transfected with 
the secreted antibody construct scFv6C7.1 (without KDEL) did not form any aggregates with Jurkat 
cells (Fig. 4.12 E1, E2), indicating the blocking ability of antibody fragment scFv6C7.1, which was 
also described for the parental antibody 6C7.1 in its IgG format (Engelhardt et al., 1998). Cells 
transfected with the secreted control construct scFv215 showed binding of Jurkat cells and formed 
“berry-like” clusters (Fig. 4.12 F1, F2).  
 
Microscopy results were analyzed by counting clusters on 25 independent images per sample. The 
number obtained with control intrabody scFv215-KDEL was set to 100% (Fig. 4.13, bar D). The 
quantity of cell clusters formed by cells transfected with the ER-retained knockdown intrabody 
scFv6C7.1-KDEL was calculated to be 47% (Fig. 4.13, bar C). This implicates that 53% of all cells 
are knocked down for VCAM-1 surface expression, which correlates well with the transfection rate 
of 52%. This indicates a close to complete functional knockdown of surface VCAM-1. In 
comparison, cells transfected with the secreted antibody construct scFv6C7.1 (without KDEL) 
showed only 32% of cluster formation (Fig. 4.13, bar E), 15% less than cells transfected with the 
ER-retained construct. The secreted antibody fragment scFv6C7.1 not only binds to transfected 
cells, but also to neighboring cells, blocking the surface VCAM-1 and inhibiting the binding of Jurkat 
cells.  
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Fig.  4.13: Statistics of cell-cell adhesion assay 
For statistical analysis, clusters per field are shown in percent as counted on 25 independent 
images. The number of clusters obtained with control construct scFv215-KDEL was set to 
100%.  
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4.10 Intrabody scFv6C7.1-KDEL is retained in transfected cells  
To distinguish whether the effects seen in cell-cell adhesion assays were due to intracellular 
knockdown of VCAM-1 or due to blocking scFv antibody fragments, the medium of transfected cells 
was analyzed. Therefore, HEK-293:VCAM-YFP cells were transiently transfected with antibody 
constructs and the medium was transferred to fresh HEK-293:VCAM-YFP cells. After overnight 
incubation, Jurkat cells were added to determine their adhesion behavior. 
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Fig.  4.14: Cell-cell adhesion of treated HEK-293:VCAM-YFP cells and Jurkat cells 
HEK-293:VCAM-YFP cells were incubated with: medium of untransfected HEK-293:VCAM-
YFP cells (A, pos. control); blocking VCAM-1 specific antibody 6C7.1 (B, neg. control); 
medium of cells that were transfected with knockdown construct scFv6C7.1-KDEL (C); 
medium of cells that were transfected with control intrabody construct scFv215-KDEL (D); 
medium of cells that were transfected with secreted control construct scFv6C7.1 (E); 
medium of cells that were transfected with secreted control construct scFv215 (F).  
 
 
Jurkat cells bound to HEK-293:VCAM-YFP cells that were incubated with medium of untransfected 
cells and formed characteristic “berry-like” clusters (Fig. 4.14 A, positive control). Cells incubated 
with VCAM-1 specific antibody 6C7.1 that is blocking VCAM-1 antigen did not form any aggregates 
with Jurkat cells (Fig. 4.14 B, negative control). This shows that aggregation of HEK-293:VCAM-
YFP and Jurkat cells depended on an interaction between VCAM-1 and VLA-4 and was inhibited 
by the blocking antibody 6C7.1. Cells incubated with medium of cells that were transfected with the 
knockdown intrabody construct scFv6C7.1-KDEL showed adhesion to Jurkat cells (Fig. 4.14 C). 
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This shows that the knockdown intrabody is effectively retained in transfected cells due to its ER-
retention sequence KDEL. HEK-293:VCAM-YFP cells incubated with medium of cells that were 
transfected with control intrabody construct scFv215-KDEL also showed a clear binding of Jurkat 
cells and formation of clusters (Fig. 4.14 D, unspecific control). However, cells incubated with 
medium of scFv6C7.1-transfected cells did not form any aggregates with Jurkat cells (Fig. 4.14 E), 
showing that scFv6C7.1 (without KDEL) was secreted by transfected cells. When the medium was 
transferred to fresh HEK-293:VCAM-YFP cells, the antibody bound to surface VCAM-1 and 
blocked binding of Jurkat cells. Cells incubated with medium of scFv215-transfected cells formed 
“berry-like” clusters with Jurkat cells (Fig. 4.14 F, unspecific control).  
 
An immunoblot and ELISA were performed to see whether the amounts of expressed VCAM-1 
specific antibodies were significantly different in cells that were transfected with constructs 
encoding ER-retained scFv6C7.1-KDEL or secreted scFv6C7.1. Therefore, the transfected cells 
were either lysed (fraction “intracellular”), or the supernatants of the cells were analyzed (fraction 
“medium”).  
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Fig.  4.15: Analysis of intracellular and medium fractions of HEK-293:VCAM-YFP cells 
Immunoblot (A): Intracellular (intracell.) or medium (med.) fractions of cells that were 
transfected with construct scFv6C7.1-KDEL or scFv6C7.1 were analyzed. Detection was 
performed via myc-tag. ELISA (B): Medium of cells that were transfected with construct 
scFv6C7.1-KDEL or scFv6C7.1 was analyzed. Detection was performed via myc-tag. 
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For the knockdown intrabody scFv6C7.1-KDEL, a strong protein band at the expected relative 
molecular mass of about 30 kDa was detected in the immunoblot of the intracellular fraction 
(Fig. 4.15 A). Barely any protein was detectable in the medium fraction of the same construct, 
indicating that the intrabody was retained inside the cells due to its ER-retention sequence KDEL. 
However, cells transfected with construct scFv6C7.1 (without KDEL) secreted the antibody into the 
medium, because the antibody was lacking the ER-retention sequence KDEL. The summarized 
total protein levels of the ER-retained and secreted antibody fragment were almost equal, but the 
intracellular protein level was much higher for the ER-retained intrabody fragment scFv6C7.1-
KDEL.  
 
Furthermore, the medium fractions were analyzed by ELISA and their specific binding to 
recombinant murine VCAM-1 antigen was verified. The medium fraction of the ER-retained 
intrabody scFv6C7.1-KDEL showed much lower signals than the secreted antibody fragment 
scFv6C7.1 (Fig. 4.15 B). These data show that intrabody scFv6C7.1-KDEL was retained in the ER 
due to its KDEL sequence, whereas antibody fragment scFv6C7.1 lacking the KDEL sequence was 
secreted into the medium. 
 
 
4.11 Intrabody scFv6C7.1-KDEL is colocalized with VCAM-YFP fusion antigen 
Confocal microscopy was used to analyze whether the retained VCAM-YFP antigen is colocalized 
with the VCAM-1 specific intrabody. Therefore, HEK-293:VCAM-YFP cells were transiently 
transfected with intrabody constructs. To maintain the morphology of cells as native as possible, 
magnetofection was used as method of transfection. The intrabodies were detected intracellularly 
via their His-tags.  
In untransfected cells, VCAM-YFP antigen was visible in the yellow fluorescence channel 
(Fig. 4.16 A), while His-specific staining did not yield any signals in the red fluorescence channel, 
as anticipated (Fig. 4.16 B). The merged image of yellow, red and blue fluorescence channel is 
shown as overlay (Fig. 4.16 D). Furthermore, there is no bleed-through of the yellow VCAM-YFP 
into the red fluorescence channel (Fig. 4.16 B). Additionally, unspecific binding of the 
AlexaFluor546-conjugated secondary antibody to cells could be excluded (data not shown).  
Cells transfected with knockdown intrabody construct scFv6C7.1-KDEL showed identical 
localization patterns for the retained antigen VCAM-YFP (Fig. 4.16 E) and the intrabody 
(Fig. 4.16 F and H). To quantify the amount of overlap, a colocalization coefficient was calculated. 
The Manders’ colocalization coefficient M1 is defined as the ratio of the ‘summed intensities of 
pixels from the green image for which the intensity in the red channel is above zero’ to the ‘total 
intensity in the green channel’ and M2 is defined conversely for red (Bolte et al., 2006). M values 
range from 0 for non-overlapping to 1 for 100% colocalization. For knockdown intrabody construct 
scFv6C7.1-KDEL the calculated M2 value was 0.608, whereas it was 0.000 for untransfected cells 
(Fig. 4.17). This strong colocalization supports the hypothesis that specific interaction of VCAM-
YFP antigen and VCAM-1 specific intrabody knocks down surface VCAM-1.  
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Fig.  4.16: Colocalization of VCAM-YFP antigen and intrabody scFv6C7.1-KDEL 
HEK-293:VCAM-YFP cells were transiently transfected using magnetofection with intrabody 
constructs scFv6C7.1-KDEL (E-H) or scFv215-KDEL (I-L). Untransfected HEK-293:VCAM-YFP 
cells were used for control (A-D). The expressed intrabodies were detected intracellularly via their 
His-tags using mouse anti-His6 and AlexaFluor546-conjugated goat anti-mouse antibodies. The 
VCAM-YFP fusion protein was detected via its yellow fluorescence. Nuclei were counterstained 
with DAPI and cells were analyzed via confocal microscopy. Scale bars represent 10 µm.  
 
 
For control, cells were transfected with the unspecific intrabody construct scFv215-KDEL. Due to 
its KDEL sequence, the antibody fragment is retained within the cell (Fig. 4.16 J and L). Here, 
some overlap is expected as both molecules are synthesized in the ER. Therefore, the Manders’ 
overlap coefficient was 0.302 (Fig. 4.17), strongly supporting that the colocalization of VCAM-YFP 
antigen and VCAM-1 specific intrabody is due to specific intracellular binding of the latter.  
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Fig.  4.17: Manders’ colocalization coefficients 
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5 Discussion  
During the last years, there have been several different attempts to silence gene expression or to 
downregulate protein function. The main goal of these studies was the investigation of unknown 
protein functions in vitro and in vivo. One of the methods applied was the generation of gene-
targeted knockout animals. In 2006, Andrew Z. Fire and Craig C. Mello shared the Nobel Prize in 
Physiology or Medicine for their work on RNA interference (RNAi) (Fire et al., 1998). During the last 
years, most attempts to silence gene expression have been done using RNAi. This powerful 
technology acts on the posttranscriptional level and has the advantage of being cheap and 
relatively easy to apply. However, fast mRNA turnover or slow protein turnover can result in little or 
no effect of RNAi on the expression levels of the targeted gene-product (Stocks, 2005). 
Additionally, unspecific off-target effects can occur when the introduced RNA is complementary to 
various genes and therefore reduces the production of multiple proteins (Qiu et al., 2005). When 
VCAM-1 was downregulated by vector-based siRNA, non-specific effects were reported, including 
upregulation of molecules associated with cellular stress response and inhibition of cell growth 
(Alam et al., 2006).  
 
Knockdown strategies using intracellular antibodies could be an alternative to RNAi derived 
technologies. The main advantage of using intrabodies is that the inhibition takes place at the 
protein level. By using such a strategy, it is possible to target specific conformations or 
posttranslational modifications of the target antigen (Nizak et al., 2003). Furthermore, knockdowns 
based on intrabodies benefit from the high specificity and affinity of antibodies (Heng et al., 2005). 
Another advantage is that the expression of antibodies in mammalian cells is very stable compared 
to siRNA (Fish et al., 2004).  
Intracellular antibodies have been used in several studies to knockdown different proteins, 
including tumor associated antigens such as ErbB-2 (Arafat et al., 2000) and viral proteins like the 
HIV-1 co-receptor CXCR4 (Mukhtar et al., 2005) or the Hepatitis C Virus core protein (Heintges et 
al., 1999). The intrabody technology has been reviewed recently (Böldicke, 2007). 
 
In this study the knockdown of surface VCAM-1 by co-expression of ER-retained intrabodies was 
investigated. Multiple parameters that may affect the downregulation of surface proteins were 
analyzed.  
 
A prokaryotic expression vector was constructed that is encoding a VCAM-1 specific scFv antibody 
fragment. The genetic information of the variable heavy and light chains of this antibody fragment 
was isolated from hybridoma cell clone 6C7.1 (Engelhardt et al., 1998). The antibody fragment 
scFv6C7.1 was expressed in E. coli and showed specific binding to VCAM-1 in vitro. Analogously, 
two mammalian expression vectors were generated, encoding the VCAM-1 specific antibody 
fragment containing or lacking the C-terminal ER-retention sequence KDEL (Munro et al., 1987), 
respectively.  
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To investigate whether these two plasmids are able to downregulate VCAM-1 on the surface of 
mammalian cells, a recombinant HEK-293 cell line had to be generated that is expressing VCAM-1 
antigen on its cell surface. Indeed, primary endothelial cells endogenously express VCAM-1, but 
they require stimulation with TNF-α to reach a detectable surface expression of VCAM-1 (Osborn 
et al., 1989). For this study, a recombinant cell line was desirable, which constitutively expressed 
VCAM-1 on its cell surface to allow a meaningful documentation of the knockdown of surface 
VCAM-1.  
Therefore, a mammalian expression vector was generated encoding a fusion protein of VCAM-1 
antigen and yellow fluorescence protein (YFP). This fusion protein allowed the measurement and 
localization of VCAM-1 by fluorescence detection of the YFP moiety (Nagai et al., 2002). Moreover, 
the strong and constitutive CMV promotor was used to obtain high expression levels of the 
recombinant VCAM-YFP fusion antigen. This strong overexpression was applied on purpose to 
demonstrate the efficiency and completeness of knockdowns obtained with intracellular antibodies.  
 
The cell surface levels of VCAM-1 were determined by extracellular staining with an additional 
VCAM-1 specific detection antibody. Therefore, a pair of VCAM-1 specific antibodies was used in 
this study, one antibody for intracellular knockdown and the other one for surface detection of 
VCAM-1. Thus, surface plasmon resonance was used (Johne, 1998) to show that both antibodies 
do not sterically interfere during binding of the VCAM-1 antigen.  
 
In order to study the expression of antibody fragments, stable VCAM-1 expressing cells were 
transfected with plasmids encoding secreted or intracellular antibody fragments that were either 
specific for VCAM-1 or unspecific (as control). All of these antibody fragments contained a His-tag 
for detection.  
When VCAM-1 expressing cells were transfected with a plasmid encoding the secreted VCAM-1 
specific antibody fragment scFv6C7.1 (without KDEL), a surprisingly high number of 91% of cells 
were positive for surface His-tag. This finding was unexpected, because only 52% of cells were 
transfected with the antibody construct according to the overall transfection efficiency. However, 
the high percentage of cells that were positive for surface His-tag might be explained by the fact 
that the transfected cells express and secrete the antibody fragment into the cell culture medium. 
The VCAM-1 specific antibody fragment might bind to VCAM-1 positive neighboring cells that 
thereby appear to be His-tag positive although they were not transfected themselves.  
Furthermore, VCAM-1 expressing cells were transiently transfected with a knockdown construct 
encoding the VCAM-1 specific intrabody scFv6C7.1-KDEL. In this case, 85% of cells were positive 
for extracellular His-tag. This result was also not expected, because the KDEL sequence should 
cause ER-retention. Cell stress caused by transient transfection via lipofection may account for this 
effect. It can be assumed that lysed cells may release intracellular proteins into the medium, 
including the scFv6C7.1-KDEL. These VCAM-1 specific antibody fragments could then bind to their 
target on the surface of neighboring cells, leading to this high number of cells being positive for 
extracellular His-tag.  
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In another study, Böldicke et al. (2005) used a cell line that was stably transfected with vascular 
endothelial growth factor receptor (VEGFR-2) and an intrabody fragment that was specific for 
VEGFR-2, containing a myc-tag and the ER-retention sequence KDEL. When an extracellular 
control staining of living cells was performed with an anti-myc antibody, no intrabody fragment was 
detected on the cell surface. However, Böldicke et al. used a stable transfection with the 
intracellular antibody and therefore cell stress shortly after transfection was not an issue.  
 
After it was shown that the encoded antibody fragments were expressed correctly, it was analyzed 
whether VCAM-1 specific intrabodies lead to a downregulation of surface VCAM-1. When VCAM-1 
expressing cells were transfected with the ER-retained knockdown construct scFv6C7.1-KDEL, the 
surface expression of VCAM-1 was significantly reduced. Two days after transfection, 22% of all 
cells showed a complete downregulation of surface VCAM-1. Taking into account the average 
transfection efficiency of 52%, this corresponds to 43% of transfected cells. Four days after 
transfection, already 48% of all cells showed a downregulation of surface VCAM-1, relating to 94% 
of transfected cells. Therefore, the surface knockdown of VCAM-1 was time-dependent with a 
maximal effect four days after transfection. These results are comparable to another study, where a 
cell line was stably transfected with an ER-retained antibody fragment specific for VEGFR-2 and 
approximately 95% of cells lost their VEGFR-2 surface expression (Böldicke et al., 2005).  
By using transient transfection with the knockdown constructs in this study, the importance of time 
from transfection to assay was underlined, a factor that has to be taken into account whenever 
surface proteins are downregulated with intrabodies. This study shows that intracellular antibodies 
efficiently downregulate surface VCAM-1 in a time-dependent manner.  
It has been published before that transfection with ErbB-2 specific ER-retained antibodies led to a 
time-dependent downregulation with cell surface ErbB-2 levels progressively declining from 48 to 
96 hours post-transfection (Curiel et al., 2000). At 96 hours post-transfection, more than 90% of 
cells showed a knockdown of surface ErbB-2. This percentage is comparable to the mentioned 
94% of cells that were downregulated for surface VCAM-1 in this study.  
 
Expression of the antibody fragment scFv6C7.1 (without KDEL) did not affect VCAM-1 surface 
expression, suggesting that the cells’ machinery for protein production and secretion is not blocked 
by the expression of the antibody fragments.  
Finally, cells were transfected with the unspecific control antibody fragment scFv215 containing or 
lacking the KDEL-sequence. Two days after transfection, both control constructs led to a slight 
decrease in surface VCAM-1 expression on a small cell population that disappeared 96 h after 
transfection. This unspecific effect is probably related to the expression of antibody fragment 
scFv215 (Liu et al., 1999). The folding of scFv215 is probably more difficult than the folding of the 
VCAM-1 specific antibody fragment. This could lead to unspecific downregulation of cellular 
proteins including the VCAM-1 surface levels. Interestingly, this effect was absent 96 h after 
transfection. 
 
  Discussion 
 50  
The downregulation of surface VCAM-1 was not only analyzed by flow cytometry but additionally by 
fluorescence microscopy. In both methods, surface VCAM-1 was determined by using VCAM-1 
specific detection antibodies. Comparable to the results obtained by flow cytometry, the images 
from fluorescence microscopy showed two different cell populations when VCAM-1 expressing 
cells were transiently transfected with the ER-retained knockdown construct. If it is taken into 
account that only every second cell was transfected (according to the determined transfection 
efficiency of 52%), only untransfected cells were still expressing surface VCAM-1, whereas cells 
that were transfected with the knockdown construct showed a surface VCAM-1 downregulation.  
To determine the percentages of cells with downregulated VCAM-1 surface expression, the 
immunofluorescence results were visually quantified. 57% of cells transfected with the ER-retained 
knockdown construct scFv6C7.1-KDEL showed a downregulation of surface VCAM-1. For cells 
transfected with control constructs scFv215 containing or lacking the KDEL-sequence, 24% and 
26% of cells showed reduced surface VCAM-1 levels, respectively.  
These high percentages for control antibody 215 can be compared to the data obtained before. 
Flow cytometry revealed that only 3% of cells that were transfected with the construct scFv215-
KDEL or scFv215 showed downregulated surface VCAM-1. The high percentages for the results 
that were obtained by fluorescence microscopy can be explained by the subjective visual method 
that was used to determine the level of VCAM-1 expression. In contrast, flow cytometry detectors 
are much more sensitive, particularly for low fluorescence intensities.  
 
In order to analyze the functionality of the VCAM-1 knockdown, a cell-cell adhesion assay was set 
up using VCAM-1 expressing HEK-293:VCAM-YFP cells and Jurkat cells. Jurkat cells are derived 
from human acute T cell leukemia and are expressing the α4β1 integrin VLA-4 on their cell surface, 
which is a physiological interaction partner of VCAM-1.  
Jurkat cells bound to HEK-293:VCAM-YFP cells and formed characteristic “berry-like” clusters. 
When HEK-293:VCAM-YFP cells were transfected with the ER-retained VCAM-1 specific 
knockdown construct scFv6C7.1-KDEL, the formation of cluster structures was almost completely 
impaired. Therefore, the knockdown of surface VCAM-1 prevented cell-cell interaction with VLA-4 
positive Jurkat cells, demonstrating that the functionality of surface VCAM-1 is also downregulated. 
Interestingly, only one to two (1.5 +/- 0.7) adhesion bonds between VCAM-1 and VLA-4 are 
sufficient to provide specific cell-cell adhesion (Zwartz et al., 2004). In light of these results, it 
becomes evident that the knockdown of surface target proteins by ER-retained antibodies is 
tremendously efficient.  
 
To study the localization of the expressed scFv antibody fragments, transfected mammalian cells 
were lysed and the intracellular fractions as well as medium supernatants were analyzed. Antibody 
fragments containing the ER-retention sequence KDEL were detected predominantly in the 
intracellular fraction, whereas scFv fragments lacking the KDEL sequence were additionally found 
in the medium. These findings are according to the study of Munro et al. (1987), who studied the 
influence of the ER-retention sequence KDEL for the first time.  
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Finally, the localization of VCAM-YFP antigen and VCAM-1 specific intrabody was analyzed using 
confocal microscopy. The antigen and the intracellular antibody fragment colocalized in the same 
cellular compartment. This supports the assumption that the specific interaction between VCAM-
YFP antigen and VCAM-1 specific intrabody leads to a downregulation of VCAM-1 from the cell 
surface. Similar colocalization results have also been published for the knockdown of several 
antigens by using ER-retained scFv antibody fragments, including VEGFR-2 (Böldicke et al., 2005) 
and viral IL-6 (Kovaleva et al., 2006).  
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6 Outlook 
Intracellular antibodies have been used in several studies to downregulate a variety of different 
antigens. Altogether, intrabodies seem to be a promising tool for the study of protein function and 
protein-protein interactions (Visintin et al., 2004). They bear exciting perspectives for the 
development of highly specific therapies (Kontermann, 2004).  
 
Until recently, it was time-consuming and labor-intensive to generate intrabodies for specific protein 
targets by using PCR amplification of the antibody genes from hybridoma cells. However, the high 
throughput generation of antibodies by recombinant systems has been started in proteome binder 
projects, so increasing amounts of recombinant antibody genes are becoming available (Konthur et 
al., 2005; Hust et al., 2007; Schofield et al., 2007; Taussig et al., 2007).  
 
In future, ER-retained intrabodies could be used in functional studies of VCAM-1 in vitro and 
in vivo. Therefore, knockdown vectors are desirable, which are inducible in a time- or tissue-
specific manner. Transgenic mice expressing an inducible VCAM-1 specific intrabody would 
supposably show VCAM-1 protein knockdown shortly after induction. This approach would 
probably be simpler than conventional methods for gene knockout and could be used to study 
VCAM-1 function at specific stages in mouse development.  
 
Additionally, a future therapeutic application of VCAM-1 specific ER-retained intrabodies could also 
be an option. Cell adhesion blockage in general is an emerging strategy in therapeutics of 
inflammatory diseases (Dedrick et al., 2003). The disruption of VCAM-1/VLA-4 interaction by 
monoclonal antibodies has been shown to be beneficial in autoimmune diseases like multiple 
sclerosis (Rudick et al., 2004). Furthermore, VCAM-1 is highly overexpressed in some tumors and 
probably plays a role in tumor immune escape (Wu, 2007).  
Thus, the development of reliable gene transfer systems will open up promising applications for the 
knockdown of VCAM-1 on posttranslational level by ER-retained intrabodies. Therefore, in future 
VCAM-1 knockdown by intrabodies might be used in common autoimmune diseases and cancer.  
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